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is case study was conducted in FY 2013 by the Emerging Space Oﬃce (ESO) to begin characterizing the kinds of 
opportunities and challenges encountered by small high-tech businesses who have never done R&D in space and who 
serve terrestrial versus space markets, but who have legitimate business reasons for considering space research and 
development for generating novel or improved products.   
 
e primary motivation for ESO’s interest in this investigation was to gain insight, through direct support of an emerging 
commercial space project as a case study, into the conditions important for the successful maturation of the International 
Space Station (ISS) into a multi-faceted, multi-user National Laboratory for providing social and economic bene$ts to 
the U.S. e ISS is the core of the human space%ight economic ecosystem in orbit and is the primary test-bed for 
investigating and understanding how to productively work and live in space.  
 
Other than providing funding for the $50K grant, NASA was not involved in any part of this study except as an observer.  
e entire eﬀort was conducted by Vivo Biosciences Inc. (the small business customer) and BioServe Space Technologies 
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“Congress declares that the general welfare of the United States   
requires that the Administration seek and encourage,  
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Why	  Does	  a	  Biotech	  Company	  Want	  to	  do	  
Research	  in	  Space?	  
	  
Vivo	  Biosciences	  Inc.	  (VBI)	  is	  an	  award	  winning	  
company	  with	  a	  customer	  base	  that	  includes	  major	  
pharmaceu/cal	  companies.	   (Page 11)	

	  
Their	  unique	  product	  (HuBiogel™)	  and	  3-­‐D	  /ssue	  and	  
tumor	  culture	  system	  was	  named	  by	  The	  Scien/st	  
Magazine	  as	  one	  of	  the	  Top	  Ten	  Innova/ons	  of	  2012.	  	  	  
HuBiogel™	  is	  used	  in	  the	  Rotary	  Cell	  Culture	  System,	  
which	  is	  a	  NASA	  spinoﬀ	  now	  produced	  and	  marketed	  
by	  Synthecon,	  that	  has	  some	  of	  the	  low	  shear	  and	  
turbulence	  features	  of	  microgravity	  that	  are	  
important	  in	  3D	  /ssue	  cultures.	  	  VBI’s	  HuBiogel™	  
system	  is	  used	  to	  grow	  /ssues	  and	  tumors	  for	  cancer	  
research	  and	  is	  now	  also	  a	  leading	  new	  candidate	  for	  
use	  in	  the	  selec/on	  of	  chemotherapy	  drugs	  for	  
cancer	  pa/ents.	  (Pages 12-14)	  
	  
However,	  despite	  a	  con/nuing	  series	  of	  successes,	  
VBI	  believes	  that	  they	  are	  about	  at	  the	  limit	  of	  the	  
performance	  their	  product	  can	  achieve	  on	  Earth	  and	  
gravity	  is	  the	  problem.	  	  	  
	  
To	  develop	  be\er	  life-­‐saving	  therapeu/c	  op/ons,	  VBI	  
needs	  3-­‐D	  /ssues	  and	  tumors	  that	  are	  both	  bigger	  
than	  what	  they	  can	  achieve	  on	  Earth	  and	  of	  higher	  
ﬁdelity	  to	  disease	  processes	  in	  a	  pa/ent.	  	  Reluctantly,	  
VBI	  concluded	  that	  space	  might	  be	  the	  best	  place,	  
and	  perhaps	  the	  only	  place,	  to	  get	  the	  improvements	  
in	  performance	  they	  need.	  	  
	  
Purpose	  of	  Case	  Study	  
	  
Vivo	  Biosciences	  Inc.	  (VBI)	  submi\ed	  an	  unsolicited	  
proposal	  to	  the	  Emerging	  Space	  Oﬃce	  (ESO)	  in	  2012	  and	  
was	  selected	  for	  a	  case	  study	  in	  FY	  2013.	  (Page 15)	  
From	  ESO’s	  perspec/ve,	  the	  purpose	  of	  this	  study	  was	  to	  
understand	  the	  kinds	  of	  op/ons,	  mo/va/ons	  and	  
diﬃcul/es	  encountered	  by	  small	  high	  tech	  companies	  
that	  have	  legi/mate	  business	  reasons	  for	  using	  space	  to	  
improve	  exis/ng	  products	  or	  develop	  new	  ones	  for	  a	  




VBI	  needed	  to	  know	  if	  they	  could	  grow	  tumor	  cells	  on	  
HuBiogel™	  in	  exis/ng	  ﬂight	  hardware	  well	  enough	  to	  
make	  a	  ﬂight	  inves/ga/on	  worth	  the	  eﬀort	  and	  expense	  
and	  obtain	  answers	  within	  the	  next	  three	  to	  ﬁve	  years.	  	  	  
	  
OpportuniKes	  for	  Public	  Beneﬁts	  
	  
In	  2013,	  while	  this	  Case	  Study	  was	  underway,	  VBI	  con-­‐
ducted	  a	  landmark	  study	  with	  Champion	  Oncology	  to	  
address	  the	  selec/on	  of	  chemotherapies	  for	  two	  types	  
of	  cancer:	  a	  drug	  sensi/ve	  colon	  cancer	  and	  a	  drug	  
resistant	  colon	  cancer.	  	  (Pages 11-14)	  
	  	  
Champions	  Oncology	  provides	  diagnos/c	  support	  to	  
physicians	  in	  the	  selec/on	  of	  chemotherapies.	  	  They	  
take	  cancers	  cells	  directly	  from	  a	  pa/ent,	  grow	  that	  
pa/ent's	  tumor	  in	  a	  mouse,	  then	  test	  a	  variety	  of	  dif-­‐
ferent	  chemotherapeu/c	  agents	  to	  see	  which	  drugs	  
work	  on	  that	  pa/ent's	  speciﬁc	  type	  of	  cancer.	  	  	  
	  
The	  problem	  is	  that	  it	  takes	  20-­‐30	  weeks	  to	  grow	  the	  
tumors	  in	  the	  mouse	  and	  Champions	  Oncology	  was	  
seeing	  too	  much	  variability	  in	  the	  results.	  	  
	  
In	  addi/on,	  colon	  cancer	  is	  a	  very	  aggressive	  cancer.	  	  
Thirty	  weeks	  can	  be	  too	  long	  to	  wait	  before	  star/ng	  
cancer	  therapy.	  	  This	  is	  where	  Vivo	  Biosciences	  oﬀers	  a	  
poten/ally	  signiﬁcant	  improvement.	  





Although	  gravity	  negaKvely	  aﬀects	  their	  product’s	  
performance	  on	  Earth,	  VBI	  does	  not	  know	  whether	  growing	  
tumors	  in	  space	  will	  improve	  outcomes.	  But	  if	  it	  does,	  the	  
results	  would	  be	  important	  to	  many	  research	  areas,	  including	  
selecKng	  the	  right	  chemo-­‐therapy	  opKons	  for	  paKents.	  	  This	  
is	  potenKally	  life-­‐saving	  research	  that	  could	  oﬀer	  signiﬁcant	  
near-­‐term	  beneﬁts	  to	  the	  public.	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Executive	  Summary	  
Chemotherapeu/c	  agents	  are	  poisons	  that	  
signiﬁcantly	  weaken	  the	  pa/ent.	  	  	  
	  
They	  are	  used	  because	  cancer	  cells	  are	  ojen	  weaker	  
than	  healthy	  cells	  to	  certain	  chemicals	  and	  the	  goal	  is	  
to	  eradicate	  the	  cancer	  before	  killing	  the	  pa/ent.	  	  	  
	  
Trea/ng	  a	  pa/ent	  with	  the	  wrong	  chemotherapeu/c	  
agent	  not	  only	  will	  not	  work	  to	  destroy	  the	  cancer	  
cells,	  it	  will	  also	  further	  weaken	  an	  already	  seriously	  
ill	  person.	  	  	  
	  	  
In	  a	  blind	  study	  using	  VBI’s	  technology,	  pa/ent	  
tumors	  provided	  by	  Champions	  Oncology	  were	  
grown	  in	  HuBiogel™	  at	  VBI	  and	  treated	  with	  known	  
drugs	  along	  with	  control	  samples.	  	  	  
	  
In	  the	  very	  ﬁrst	  study	  performed,	  HuBiogel™	  tests	  
were	  correct	  in	  70-­‐80%	  of	  the	  cases,	  but	  it	  only	  took	  
2-­‐3	  weeks	  to	  get	  the	  results	  and	  not	  30	  weeks.	  
	  	  
This	  speed	  can	  make	  a	  cri/cal	  diﬀerence	  for	  a	  pa/ent	  
suﬀering	  from	  colon	  cancer	  and	  other	  aggressive	  
cancers.	  	  	  
	  	  
The	  goal	  now	  is	  to	  predict	  and	  achieve	  >90%	  
accuracy	  in	  2	  week	  analyses.	  	  Achieving	  this	  
accuracy	  is	  where	  VBI	  believes	  that	  space	  research	  
could	  make	  the	  diﬀerence.	  	  
	  
	  
The	  High	  Cost	  of	  Learning	  
	  
VBI	  was	  highly	  mo/vated	  to	  make	  the	  ﬂight	  hardware	  
evalua/on	  test	  work.	  	  	  
	  
The	  insights	  gained	  from	  their	  successes	  and	  prob-­‐
lems	  are	  useful	  for	  understanding	  where	  NASA	  and	  
CASIS	  can	  play	  cri/cal	  roles	  in	  achieving	  be\er	  out-­‐
comes	  for	  public	  beneﬁts	  from	  both	  the	  ISS	  and	  the	  
emerging	  commercial	  space	  transporta/on	  and	  







$50K	  was	  provided	  via	  an	  ESO	  grant	  to	  VBI	  to	  deter-­‐
mine	  whether	  they	  could	  grow	  tumors	  in	  exis/ng	  
ﬂight	  hardware.	  	  	  
Of	  the	  	  $50K	  ESO	  funding:	  
•  $28K	  supported	  the	  Vivo	  Biosciences	  Principal	  
Inves/gator	  and	  a	  part	  /me	  temporary	  research	  
assistant	  for	  prepara/on	  and	  analyses	  of	  samples;	  
•  $11K	  went	  to	  BioServe	  Space	  Technologies	  for	  
leasing	  the	  ﬂight	  test	  unit	  (BioCell)	  and	  design	  
services;	  and	  	  
•  $11K	  went	  for	  /ssue	  culture	  supplies	  and	  
reagents	  used	  to	  grow	  and	  analyze	  the	  samples.	  	  	  
	  
The	  test	  required	  successfully	  managing	  the	  culture	  
condi/ons	  and	  ﬁxa/on	  strategies	  for	  4-­‐6	  weeks	  in	  the	  
ﬂight	  hardware	  under	  an/cipated	  space	  ﬂight	  
condi/ons.	  	  	  
	  
Then	  VBI	  evaluated	  the	  adequacy	  of	  tumor	  growth	  
and	  func/on	  in	  the	  BioCell	  using	  imaging	  and	  bio-­‐
chemical	  analyses.	   (Appendix III)	

	  
The	  results	  determined	  whether	  a	  ﬂight	  inves/ga/on	  
had	  a	  high	  probability	  of	  yielding	  new	  important	  
insights	  for	  project	  improvement.	  	  
	  	  
Ajer	  six	  months,	  Vivo	  Biosciences	  concluded	  that	  
some	  but	  not	  all	  of	  their	  technical	  goals	  could	  be	  met	  
because	  the	  culture	  chamber	  was	  too	  small.	  	  	  
	  	  
However,	  they	  did	  determine	  that	  there	  were	  no	  
fundamental	  biocompa/bility	  issues	  with	  the	  BioCell	  
materials	  and	  that	  they	  could	  manage	  the	  /ssue	  
growth	  environment	  for	  the	  necessary	  4-­‐6	  weeks.	  	  	  
	  
With	  a	  minor	  redesign	  of	  the	  ﬂight	  hardware,	  this	  
experiment	  could	  be	  conducted	  in	  space	  within	  a	  
year	  …	  if	  funds	  were	  available	  to	  support	  it.	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  Summary	  
Piballs	  and	  Pathﬁnders	  
	  
Nobody	  does	  biotech	  research	  on	  earth	  the	  way	  it	  must	  
be	  done	  in	  space.	  	  The	  procedures	  are	  not	  even	  close.	  	  
Terrestrial	  labs	  do	  not	  have	  to	  manage	  launch	  stresses,	  
unwanted	  and	  non-­‐intui/ve	  eﬀects	  of	  microgravity,	  re-­‐
entry	  stresses,	  and	  post-­‐ﬂight	  recovery	  delays.	  	  	  	  
In	  fact,	  laboratory	  research	  in	  microgravity	  is	  so	  diﬀerent	  
from	  anything	  a	  typical	  laboratory	  scien/st	  would	  expe-­‐
rience	  on	  Earth	  that	  it	  is	  akin	  to	  pursuing	  a	  graduate	  
degree	  in	  a	  new	  technical	  subject.	  	  	  
Novice	  invesKgators	  need	  considerable	  help	  to	  suc-­‐
ceed,	  especially	  if	  ﬂight	  research	  is	  only	  a	  minor	  part	  of	  
their	  business	  model.	  	  (Pages 20-26)	  
	  
Like	  Vivo	  Biosciences,	  commercial	  biotech	  research	  will	  
seek	  speciﬁc	  research	  outcomes	  that	  are	  likely	  to	  
require	  changes	  in	  ﬂight	  hardware.	  	  	  
Few	  companies,	  even	  large	  companies,	  can	  aﬀord	  to	  
spend	  $50K	  and	  six	  months	  of	  their	  own	  resources	  to	  
determine	  that	  the	  ﬂight	  hardware	  is	  not	  adequate	  for	  
their	  inves/ga/on;	  wait	  six	  months	  or	  more	  for	  a	  re-­‐
design;	  then	  spend	  an	  addi/onal	  $50K	  (or	  more)	  to	  test	  
the	  new	  hardware	  again	  before	  commipng	  to	  a	  ﬂight	  
(cos/ng	  in	  excess	  of	  $200K)	  	  that	  may	  or	  may	  not	  yield	  a	  
produc/ve	  outcome.	  	  For	  large	  companies,	  this	  is	  
una\rac/ve.	  	  For	  small	  companies,	  it	  is	  prohibi/ve.	  
	  
However,	  these	  small	  companies	  are	  oden	  the	  
pathﬁnders	  for	  new	  capabiliKes	  in	  high	  tech	  industries	  
and	  they	  oﬀer	  the	  innovaKve	  culture	  that	  can	  pioneer	  
important	  new	  uses	  for	  the	  ISS	  NaKonal	  Laboratory,	  
serving	  both	  the	  naKon	  and	  NASA’s	  interest	  well.	  
	  
	  
The	  Vivo	  Biosciences	  ﬂight	  concept:	  
  Addresses	  an	  important	  public	  need	  (cancer	  research	  
and	  applica/ons),	  
  Serves	  a	  terrestrial	  rather	  than	  ﬂight	  market,	  
  Requires	  space	  to	  achieve	  it’s	  goals	  (currently,	  
accuracy	  is	  limited	  by	  tumor	  size	  and	  characteris/cs	  
which	  are	  limited	  by	  gravity),	  	  
If	  successful,	  this	  study	  could	  result	  in	  an	  important	  
breakthrough.	  	  But	  success	  is	  by	  no	  means	  assured.	  
This	  is	  an	  exploratory	  commercial	  applica/ons	  proposal	  	  
for	  a	  terrestrial	  market,	  rather	  than	  space	  biology	  basic	  
research,	  space	  technology	  development,	  or	  space	  
biomedical	  research.	  	  
	  
Although	  Vivo	  Biosciences	  is	  a	  small	  business,	  VBI	  does	  
not	  address	  a	  space	  market	  and	  so	  is	  not	  eligible	  for	  
NASA’s	  SBIR/STTR	  funding.	  	  	  	  
	  
As	  such,	  this	  proposal	  falls	  through	  the	  cracks	  of	  
NASA’s	  R&D	  porEolio	  and	  the	  high	  risk	  nature	  of	  the	  
space	  element	  makes	  it	  unaFracGve	  to	  most	  private	  
investors.	  
	  
Parts	  That	  Work	  	  
	  
Flight	  accommoda/ons	  as	  currently	  conﬁgured	  are	  not	  
customer-­‐friendly	  for	  novices,	  although	  BioServe	  Space	  
Technologies	  provided	  excellent	  support	  to	  Vivo	  
Biosciences	  throughout	  the	  study.	  (Pages 26-32)	  
	  	  
In	  fact,	  the	  role	  of	  a	  mentor	  or	  guide	  (like	  BioServe)	  
who	  provides	  a	  bridge	  between	  the	  needs	  of	  a	  novice	  
ﬂight	  invesKgator	  and	  the	  accommodaKons	  and	  
constraints	  of	  space	  ﬂight	  is	  the	  single	  most	  essenKal	  
element	  in	  crading	  a	  successful	  research	  experience	  for	  
new	  entrants	  into	  space	  laboratories.	  	  
6	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Executive	  Summary	  
From	  VBI’s	  commercial	  perspecKve,	  that	  the	  
InternaKonal	  Space	  StaKon	  (ISS)	  is	  immediately	  and	  
permanently	  available	  for	  iteraKve	  research,	  and	  that	  
SpaceX	  Dragon	  can	  provide	  the	  criKcal	  return	  of	  
samples	  to	  earth	  as	  well	  as	  payload	  transportaKon	  to	  
the	  ISS,	  were	  all	  essenKal	  to	  VBI	  even	  considering	  
trying	  to	  improve	  their	  product	  in	  space.	  	  In	  this	  case,	  
sample	  return	  is	  a	  deal-­‐maker.	  
	  
Conclusion:	  (Pages 26-32)	  
	  	  
For	  any	  company,	  /me	  is	  money.	  	  	  
	  	  
During	  the	  six	  months	  that	  Vivo	  Biosciences	  conducted	  
the	  ESO	  Case	  Study,	  it	  also	  completed	  two	  landmark	  
studies	  for	  paying	  customers,	  which	  illustrates	  another	  
point.	  	  	  
	  	  
The	  priority	  of	  companies,	  especially	  small	  companies,	  
must	  be	  to	  support	  their	  paying	  customers	  while	  the	  
space	  ﬂight	  inves/ga/ons	  are	  being	  developed.	  	  Ojen	  
they	  won’t	  have	  the	  resources	  to	  do	  both	  with	  internal	  
funds.	  
	  	  
The	  amount	  of	  /me	  it	  takes	  to	  do	  a	  space	  ﬂight	  
inves/ga/on	  (years)	  is	  signiﬁcantly	  out	  of	  scale	  with	  a	  
commercial	  laboratory	  inves/ga/on	  on	  Earth	  (days	  to	  
weeks).	  	  	  
	  	  
Vivo	  Biosciences	  believes	  that	  removing	  gravity	  to	  
obtain	  larger,	  beher-­‐quality	  tumors	  is	  one	  of	  the	  few,	  
and	  perhaps	  the	  best,	  opKon	  it	  has	  for	  improving	  
research	  and	  cancer	  treatment	  outcomes	  with	  their	  
product.	  (Pages 16-19)	  
	  
But	  it	  s/ll	  might	  not	  work	  and	  they	  can’t	  aﬀord	  to	  fund	  
the	  wrong	  strategy.	  	  	  
	  
Unfortunately,	  three	  outcomes	  are	  possible	  with	  this	  
inves/ga/on	  and,	  from	  a	  company’s	  perspec/ve	  as	  a	  
poten/al	  paying	  customer,	  	  two	  of	  them	  are	  bad.	  
	  
	  
First,	  the	  experiment	  might	  not	  work	  at	  all,	  either	  
because	  microgravity	  doesn’t	  help	  achieve	  the	  desired	  
results	  or	  because	  of	  mechanical	  problems,	  opera/onal	  
issues	  or	  simply	  bad	  experiment	  design	  resul/ng	  from	  
inexperience	  with	  space	  ﬂight	  reali/es.	  	  
	  
Alterna/vely,	  there	  may	  be	  some	  improvements	  from	  
space	  but	  either	  they	  are	  not	  signiﬁcant	  enough	  or	  
their	  value	  is	  diminished	  by	  other	  nega/ve	  eﬀects	  of	  
growth	  in	  microgravity	  and	  the	  outcome	  turns	  out	  not	  
to	  be	  worth	  the	  cost.	  
	  	  
Third	  and	  best,	  the	  space	  ﬂight	  results	  are	  what	  the	  
commercial	  researcher	  hoped	  to	  achieve.	  	  In	  which	  
case,	  the	  company	  will	  need	  to	  ﬂy	  the	  experiment	  again	  
to	  conﬁrm	  it	  and	  then	  many	  more	  /mes	  to	  develop	  
suﬃcient	  reliability	  and	  conﬁdence	  for	  a	  marketable	  
product.	  	  This	  is	  a	  very	  expensive,	  likely	  prohibi/vely	  
expensive,	  undertaking	  for	  a	  small	  company.	  
	  	  
Unfortunately,	  there	  is	  no	  way	  to	  develop,	  or	  even	  to	  
determine,	  the	  value	  of	  removing	  gravity	  for	  
advancing	  this	  type	  of	  potenKally	  life	  saving	  research	  






Na/onally,	  there	  are	  insuﬃcient	  funds	  for	  early	  stage	  
exploratory	  applica/ons	  research,	  like	  VBI’s,	  that	  
inves/gates	  unproven	  but	  promising	  microgravity	  
techniques	  and	  addresses	  a	  terrestrial	  versus	  space	  
market.	  	  
	  	  
In	  fact,	  if	  the	  government	  does	  not	  help	  this	  new	  ﬁeld	  
of	  laboratory	  sciences	  to	  grow,	  it	  is	  unlikely	  to	  develop	  
the	  criKcal	  mass	  of	  talent	  and	  ideas	  necessary	  to	  
achieve	  the	  number	  and	  kinds	  of	  breakthroughs	  that	  
can	  oﬀer	  important	  new	  outcomes	  for	  the	  taxpayers’	  
investments.	  	  Alone,	  CASIS’	  funding	  is	  insuﬃcient	  to	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Executive	  Summary	  
The	  ISS	  and	  commercial	  space	  synergy	  are	  capable	  of	  
delivering	  even	  more	  value	  to	  the	  public	  than	  the	  
many	  contribu/ons	  they	  have	  already	  achieved.	  	  
	  
Therefore,	  it	  is	  strongly	  recommended	  that	  NASA	  
establish	  funded	  solicitaKon	  mechanisms	  to	  encou-­‐
rage	  worthy	  applicaKons	  R&D	  in	  space,	  at	  least	  
through	  the	  iniKal	  ﬂight	  test,	  when	  such	  studies	  have	  
the	  potenKal	  to	  yield	  important	  public	  beneﬁts,	  even	  
if	  they	  don’t	  provide	  a	  NASA	  applicaKon	  or	  ﬁt	  within	  
standard	  programmaKc	  boundaries.	  
	  
Mentors,	  advisors,	  guides	  and	  integrators	  (MAGIs)	  who	  
can	  help	  a	  novice	  craj	  a	  successful	  ﬂight	  experiment	  –	  	  
like	  those	  at	  Bioserve	  Space	  Technologies,	  Dr.	  
Lawrence	  DeLucas	  at	  University	  of	  Alabama,	  
Nanoracks,	  and	  inves/gator	  ﬂight	  support	  groups	  at	  
NASA	  Centers	  –	  are	  essen/al	  to	  the	  development	  of	  
the	  ISS	  Na/onal	  Laboratory	  and	  the	  commercial	  
microgravity	  laboratory	  market	  that	  could	  become	  
important	  to	  emerging	  space	  companies.	  	  	  
	  
Because	  they	  play	  such	  essenKal	  roles	  in	  delivering	  
value	  back	  to	  the	  public	  from	  spaceﬂight,	  it	  is	  recom-­‐
mended	  that	  the	  MAGIs	  be	  supported	  to	  maintain	  
criKcal	  staﬀ	  experKse	  during	  the	  intervals	  between	  
funded	  ﬂight	  developments.	  
	  
Novel	  research	  of	  the	  kind	  that	  can	  lead	  to	  
breakthroughs	  will	  almost	  always	  require	  hardware	  
modiﬁca/on.	  	  
	  
Some	  mods	  will	  be	  rela/vely	  easy	  and	  cheap,	  like	  those	  
required	  by	  Vivo	  Biosciences.	  	  
	  
But	  some	  that	  are	  important	  for	  opening	  new	  markets	  
–	  like	  onboard	  analyses	  and	  the	  ability	  to	  handle	  
sensi/ve	  biological	  samples	  on	  the	  launchpad,	  through	  
the	  launch	  interval,	  	  and	  during	  return	  to	  Earth	  –	  may	  
need	  funding	  in	  the	  $5M-­‐$10M	  category.	  	  
However,	  given	  the	  magnitude	  of	  taxpayer	  invest-­‐
ments	  to	  build	  the	  ISS	  and	  the	  billions	  of	  dollars	  per	  
year	  spent	  in	  opera/ng	  it,	  increasing	  funding	  to	  sup-­‐
port	  more	  space	  research	  for	  public	  beneﬁt	  and	  in-­‐
creasing	  the	  investment	  in	  infrastructure	  that	  makes	  
more	  breakthroughs	  possible	  is	  a	  sound	  and	  worthy	  
strategy,	  even	  with	  the	  challenges	  of	  sequestra/on.	  	  
	  
The	  Vivo	  Biosciences	  ﬂight	  concept	  is	  worth	  doing.	  	  
It	  will	  oﬀer	  valuable	  informaKon	  to	  NASA	  and	  the	  
emerging	  space	  community	  on	  the	  challenges	  facing	  
new	  commercial	  entrants	  into	  the	  ﬁeld	  of	  space	  
research	  –	  whether	  VBI	  succeeds	  in	  meeGng	  its	  
research	  objecGves	  or	  not.	  	  	  
	  
Therefore,	  it	  is	  strongly	  recommended	  that	  both	  
NASA	  and/or	  CASIS	  conKnue	  to	  support	  VBI’s	  
invesKgaKon	  through	  ﬂight	  and	  that	  ESO	  monitor	  its	  
progress	  because	  of	  its:	  
  PotenKal	  beneﬁt	  to	  public	  health;	  	  
  UKlity	  as	  a	  Case	  Study	  for	  this	  class	  of	  commer-­‐
cial	  biotech	  research	  in	  space	  for	  a	  terrestrial	  
(rather	  than	  space)	  market;	  and	  
  Value	  in	  understanding	  the	  customer	  perspecKve	  
and	  developing	  the	  commercial	  research	  and	  
applicaKons	  potenKal	  of	  the	  ISS	  and	  the	  
commercial	  space	  transportaKon	  and	  service	  
providers	  that	  are	  evolving	  with	  the	  ISS	  NaKonal	  
Laboratory.	  
	  
Finally,	  it	  is	  strongly	  recommended	  that	  NASA	  and	  
CASIS	  conKnue	  their	  wise	  pracKce	  of	  encouraging	  
and	  supporKng	  excepKons	  to	  standard	  plans	  and	  
procurement	  strategies	  for	  ﬂight	  studies	  when	  “out	  
of	  the	  box”	  and	  “out	  of	  the	  blue”	  proposals	  oﬀer	  the	  
potenKal	  for	  excepKonal	  outcomes	  that	  could	  serve	  







“Governments	  will	  always	  play	  a	  huge	  part	  in	  solving	  big	  problems.	  They	  set	  public	  policy	  and	  are	  uniquely	  
able	  to	  provide	  the	  resources	  to	  make	  sure	  solu@ons	  reach	  everyone	  who	  needs	  them.	  They	  also	  fund	  basic	  





“Biotech	  is	  all	  about	  picking	  the	  excep@on.”	  
	  
Bob	  More,	  general	  partner	  with	  Frazier	  Healthcare	  Ventures.	  
	  
	  
“Experiments	  conducted	  in	  the	  microgravity	  environment	  of	  space	  are	  not	  typically	  at	  the	  forefront	  of	  the	  
mind	  of	  a	  cancer	  biologist.	  However,	  space	  provides	  physical	  condi@ons	  that	  are	  not	  achievable	  on	  Earth,	  as	  
well	  as	  condi@ons	  that	  can	  be	  exploited	  to	  study	  mechanisms	  and	  pathways	  that	  control	  cell	  growth	  and	  
func@on.	  Over	  the	  past	  four	  decades,	  studies	  have	  shown	  how	  exposure	  to	  microgravity	  alters	  biological	  
processes	  that	  may	  be	  relevant	  to	  cancer.”	  
	  
Jeanne	  L.	  Becker	  and	  Glauco	  R.	  Souza,	  Nature	  Reviews|Cancer.	  	  Volume	  13.	  May	  2013.	  
	  
	  
People's	  view	  of	  cancer	  will	  change	  when	  they	  have	  their	  own	  rela@onship	  with	  cancer,	  which	  everyone	  will,	  





“A	  new	  survey	  of	  cancer	  researchers	  <in	  2013>	  by	  the	  American	  Society	  of	  Clinical	  Oncology	  shows	  that	  the	  
mul@year	  stagna@on	  in	  federal	  cancer	  research	  funding,	  on	  top	  of	  this	  year’s	  automa@c	  budget	  cuts	  required	  
under	  sequestra@on,	  is	  having	  a	  profound	  impact	  on	  the	  U.S.	  cancer	  research	  enterprise.	  
	  
A	  large	  majority,	  75	  percent,	  of	  survey	  respondents	  reported	  that	  the	  current	  federal	  funding	  situa@on	  is	  
having	  a	  direct	  impact	  on	  their	  ability	  to	  conduct	  cancer	  research,	  in	  many	  cases	  triggering	  “devasta@ng”	  
changes.	  Delayed	  clinical	  trials,	  the	  elimina@on	  of	  research	  staﬀ	  posi@ons,	  and	  the	  hal@ng	  or	  slowing	  of	  
promising	  research	  that	  could	  lead	  to	  new	  therapies	  for	  cancer	  were	  cited	  as	  speciﬁc	  results	  of	  stagnant	  
funding.”	  	  
	  
American	  Society	  of	  Clinical	  Oncology	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Purpose	  and	  Rationale	  
This	  case	  study	  was	  conducted	  in	  FY	  2013	  by	  the	  
Emerging	  Space	  Oﬃce	  (ESO).	  	  The	  purpose	  was	  to	  begin	  
characterizing	  the	  opportuni/es	  and	  challenges	  
encountered	  by	  small	  high-­‐tech	  businesses	  whose	  
primary	  markets	  are	  not	  related	  to	  space,	  but	  who	  have	  
legi/mate	  business	  reasons	  for	  considering	  space	  
research	  and	  development	  for	  genera/ng	  novel	  or	  
improved	  products.	  	  	  
A	  biotech	  company	  was	  chosen	  for	  this	  case	  study	  
because	  	  their	  product	  oﬀers	  direct	  beneﬁts	  to	  the	  
public,	  addresses	  a	  mature	  and	  growing	  $93B	  U.S.	  
industry,	  and	  because	  while	  there	  is	  strong	  evidence	  
that	  space	  ﬂight	  can	  oﬀer	  important	  advances	  in	  this	  
ﬁeld,	  there	  is	  not	  yet	  suﬃcient	  proof	  to	  a\ract	  a	  wide	  
range	  of	  paying	  customers	  for	  space	  research	  services.	  
The	  primary	  mo/va/on	  for	  ESO’s	  interest	  in	  this	  
inves/ga/on	  was	  to	  gain	  insight,	  through	  direct	  support	  
of	  an	  emerging	  commercial	  space	  project	  as	  a	  case	  
study,	  into	  the	  condi/ons	  important	  for	  the	  successful	  
matura/on	  of	  the	  ISS	  into	  a	  mul/-­‐faceted,	  mul/-­‐user	  
Na/onal	  Laboratory	  that	  provides	  increasing	  social	  and	  





The	  Interna/onal	  Space	  Sta/on	  (ISS)	  is	  the	  core	  of	  the	  
human	  spaceﬂight	  economic	  ecosystem	  in	  orbit	  and	  is	  
the	  primary	  test-­‐bed	  for	  inves/ga/ng	  and	  under-­‐
standing	  how	  to	  produc/vely	  work	  and	  live	  in	  space.	  	  
Achieving	  the	  fullest	  possible	  commercial	  u/liza/on	  of	  
the	  ISS	  is	  vital	  to	  delivering	  a	  return	  to	  the	  American	  
taxpayers	  for	  their	  investment	  in	  the	  ISS,	  as	  well	  as	  
vital	  to	  NASA	  as	  it	  develops	  long-­‐term	  sustainable	  
spaceﬂight	  and	  space	  explora/on	  in	  Earth	  orbit	  and	  
beyond.	  	  
Ensuring	  the	  full	  u/liza/on	  of	  the	  ISS	  requires	  
understanding	  the	  needs	  of	  emerging	  commercial	  
en//es	  as	  they	  develop	  spaceﬂight	  projects	  for	  the	  
ﬁrst	  /me,	  as	  well	  as	  understanding	  the	  challenges	  that	  
spaceﬂight	  presents	  for	  commercial	  par/cipants,	  and	  
what	  NASA	  can	  do	  to	  help	  to	  ensure	  that	  as	  many	  
worthy	  U.S.	  organiza/ons	  as	  possible	  are	  able	  to	  
surmount	  these	  challenges.	  	  	  
The	  insights	  gained	  in	  this	  study	  is	  also	  relevant	  to	  
emerging	  space	  companies	  like	  SpaceX,	  Orbital	  
Sciences,	  and	  Bigelow	  Aerospace,	  who	  may	  be	  looking	  
to	  a\ract	  this	  type	  of	  high	  tech	  customer.	  	  
This	  report	  is	  not	  wri\en	  for	  bioscien/sts	  but	  rather	  
for	  knowledgeable	  professionals	  in	  other	  technical	  
disciplines	  who	  may	  have	  to	  make	  decisions	  regarding	  
support	  for	  these	  types	  of	  commercial	  space	  biotech	  
inves/ga/ons.	  	  	  
The	  following	  insights	  have	  been	  derived	  from	  direct	  
engagement	  with	  the	  researchers	  involved	  in	  this	  
par/cular	  case	  study	  but	  with	  no	  other	  NASA	  role	  





is report, references and appendices can be downloaded at:  https://sites.google.com/site/esocasestudyvivobiosciences/home 
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The	  Case	  Study	  focused	  on	  Vivo	  Biosciences	  Inc.	  
(VBI),	  an	  award-­‐winning	  	  small	  biotech	  business	  
concentrated	  on	  3-­‐D	  /ssue	  engineering	  primarily	  
for	  cancer	  research,	  treatment	  selec/on,	  and	  
tes/ng.	  (Ref 1, 2)	

VBI	  customers	  include	  pharmaceu/cal	  giants	  such	  
as	  Merck,	  Johnson&Johnson,	  Astellas,	  Janssen,	  
Roche,	  and	  Novar/s,	  	  as	  well	  as	  smaller	  but	  highly	  
respected	  cupng-­‐edge	  cancer	  research	  companies	  
including	  Molecular	  Response	  and	  Champion	  
Oncology. (Ref 3)	

Vivo	  Biosciences’	  product	  HuBiogel™	  (US	  Patent:	  
7,727,750,	  2010:	  Novel	  human	  biomatrix	  scaﬀold	  
for	  normal	  &	  disease	  models)	  addresses	  important	  
medical	  topics	  including	  cancer	  and	  stem	  cell	  
research	  and	  is	  now	  beginning	  to	  emerge	  as	  one	  of	  
the	  leading	  candidates	  for	  the	  selec/on	  of	  chemo-­‐








Why	  Microgravity?	  	  
	  
The	  CEO	  of	  Vivo	  Biosciences,	  Dr.	  Raj	  Singh	  is	  con-­‐
cerned	  that	  VBI	  may	  be	  approaching	  the	  limits	  of	  
what	  their	  product	  can	  oﬀer	  medical	  research	  and	  
treatment	  selec/on,	  and	  that	  the	  limita/on	  in	  product	  
performance	  is	  caused	  by	  gravity.	  	  	  He	  does	  not	  know	  
if	  research	  in	  microgravity	  can	  help,	  but	  it	  is	  one	  of	  
the	  only	  op/ons	  his	  company	  has	  to	  overcome	  nega-­‐
/ve	  gravita/onal	  eﬀects.	  (Ref 5)	

	  
Their	  primary	  product	  line	  is	  used	  in	  conjunc/on	  with	  
the	  NASA	  developed	  rotary	  cell	  culture	  system,	  now	  
marketed	  by	  Synthecon,	  which	  mimics	  a	  number	  of	  
microgravity	  features	  important	  for	  producing	  high	  
quality	  3-­‐D	  cell	  cultures. (Ref 6)	

	  
Prior	  space	  ﬂight	  results	  and	  the	  excep/onal	  
performance	  of	  the	  Synthecon	  Rotary	  Cell	  Culture	  
System	  with	  its	  features	  of	  low	  shear	  and	  turbulence	  
(features	  that	  are	  even	  more	  eﬀec/ve	  in	  microgravity)	  
led	  the	  CEO	  of	  Vivo	  Biosciences,	  Dr.	  Raj	  Singh,	  to	  
consider	  using	  space	  microgravity	  to	  improve	  the	  
performance	  of	  his	  product	  for	  cancer	  research	  and	  
clinical	  applica/ons.	  (Ref 7)	

 
VBI	  is	  looking	  to	  develop	  larger	  3-­‐D	  Kssue	  
models	  that	  more	  accurately	  simulate	  the	  
behavior	  of	  the	  disease	  in	  the	  human	  body	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3-­‐D	  /ssue	  engineering	  of	  the	  kind	  that	  VBI’s	  primary	  
product	  supports	  is	  about	  growing	  larger	  and/or	  be\er	  
/ssues,	  where	  the	  size	  (mul@cellular	  construct)	  is	  
essen/al	  to	  higher	  quality	  for	  medical	  research.	  	  	  	  
"Be&er"	  is	  speciﬁc	  to	  the	  disease	  biology	  being	  
studied,	  changes	  with	  each	  disease,	  and	  is	  the	  metric	  
of	  value.	  
	  
The	  most	  important	  data	  from	  in	  vitro*	  studies	  are	  
whether	  the	  Kssues	  in	  culture	  exhibit	  characterisKcs	  
found	  in	  paKents	  suﬀering	  from	  a	  disease	  with	  
enough	  ﬁdelity	  to:	  	  
  Determine	  what	  causes	  a	  disease	  	  
  Understand	  how	  a	  disease	  progresses	  	  
  IdenKfy	  therapeuKc	  targets	  to	  interrupt	  or	  stop	  
the	  disease	  process	  
  Enable	  very	  high	  ﬁdelity	  tesKng	  of	  treatments.	  	  
Using	  this	  informa/on,	  researchers	  can	  determine	  






"e development and validation of reliable in vitro methods alternative to conventional in vivo studies in experimental 
animals is a well-recognized priority in the "elds of pharmaco-toxicology and food research. Conventional studies based on 
two-dimensional (2-D) cell monolayers have demonstrated their signi"cant limitations: the chemically and spatially de"ned 
three-dimensional (3-D) network of extracellular matrix components, cell-to-cell and cell-to-matrix interactions that governs 
diﬀerentiation, proliferation and function of cells in vivo is, in fact, lost under the simpli"ed 2-D condition. Being able to 
reproduce speci"c tissue-like structures and to mimic functions and responses of real tissues in a way that is more physiologically 
relevant than what can be achieved through traditional 2-D cell monolayers, 3-D cell culture represents a potential bridge to 
cover the gap between animal models and human studies. (Ref 8) 
 
Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? Giovanna Mazzoleni, D. Di Lorenzo, and N. Steimberg 
* in vitro is de"ned as "outside the living body and in an arti"cial environment" e.g., 3-D tissue cultures 
** in vivo is de"ned as "in the living body of a plant or animal,” e.g., in the patient’s body 
	  
suﬃciently	  well	  to	  mi/gate	  or	  cure	  it,	  and	  with	  as	  few	  
side	  eﬀects	  as	  possible.	  (Ref 9)	  
High	  quality	  /ssues	  that	  behave	  as	  a	  pa/ent's	  /ssues	  do	  
in	  vivo**	  can	  also	  be	  used	  to	  test	  therapeu/c	  strategies.	  	  	  
The	  quality	  of	  the	  results	  depends	  en/rely	  upon	  how	  well	  
a	  /ssue	  mimics	  what	  happens	  in	  the	  body	  (in	  vivo).	  
This	  year	  VBI	  demonstrated	  that	  microtumors	  grown	  in	  
its	  product	  behaved	  as	  they	  did	  in	  certain	  cancer	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One	  important	  reason	  that	  researchers	  are	  
interested	  in	  growing	  larger	  /ssues	  with	  the	  right	  
characteris/cs	  is	  to	  study	  the	  "ecology"	  of	  the	  
spread	  of	  a	  disease,	  i.e.	  how	  the	  environment	  
around	  the	  tumor	  or	  infec/on	  inhibits	  or	  
enhances	  virulence.	  	  If	  there	  are	  no	  eﬀec/ve	  
therapeu/cs	  to	  a\ack	  a	  disease	  directly,	  
researchers	  are	  looking	  for	  ways	  to	  aﬀect	  the	  
environment	  surrounding	  the	  aﬀected	  /ssue	  to	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In	  a	  recent	  R&D	  collabora/on	  with	  NovarKs	  Genomic	  
InsKtute,	  VBI	  produced	  hundreds	  of	  3-­‐D	  human	  tumors	  
and	  compared	  drug	  response	  and	  gene	  expression	  proﬁles	  
with	  2-­‐D	  cultures	  and	  in	  vivo	  studies.	  Results	  from	  ﬁve	  
independent	  projects,	  validated	  that	  3-­‐D	  tumor	  biology	  
and	  gene	  targets	  matched	  with	  in	  vivo	  data	  but	  not	  with	  2-­‐
D	  assay	  outcomes.	  This	  further	  highlights	  the	  physiological	  







A	  factor	  limiKng	  the	  size	  and	  quality	  of	  3-­‐D	  Kssue	  
and	  organ	  cultures	  on	  Earth	  is	  gravity.	  	  Regardless	  of	  
the	  /ssue	  culture	  strategies	  used	  to	  overcome	  gravita-­‐
/onal	  eﬀects	  on	  Earth,	  when	  the	  /ssues	  grow	  to	  a	  size	  
that	  allows	  important	  new	  insights	  to	  be	  gained,	  the	  
techniques	  used	  to	  prevent	  the	  /ssues	  from	  se\ling	  to	  
the	  bo\om	  of	  a	  culture	  system	  are	  increasingly	  
perturbing,	  eventually	  damaging	  the	  /ssues	  to	  the	  point	  
that	  they	  become	  too	  unreliable	  for	  research.	  (Ref 13)	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While	  the	  Case	  Study	  was	  underway,	  Champions	  
Oncology	  partnered	  with	  Vivo	  Biosciences	  to	  use	  
HuBiogel™	  to	  address	  the	  selec/on	  of	  chemotherapies	  
for	  two	  types	  of	  cancer:	  a	  drug	  sensi/ve	  and	  a	  drug	  
resistant	  colon	  cancer.	  (Ref 14)	  	  
Champions	  Oncology	  provides	  diagnos/c	  support	  to	  
physicians	  using	  a	  mouse	  model	  to	  select	  chemo-­‐
therapies.	  	  They	  grow	  an	  individual	  pa/ent's	  tumor	  in	  
a	  mouse,	  then	  test	  a	  variety	  of	  diﬀerent	  therapeu/c	  
agents	  to	  see	  which	  drugs	  work	  on	  that	  speciﬁc	  
pa/ent's	  type	  of	  cancer.	  	  The	  problem	  is	  that	  it	  takes	  
20-­‐30	  weeks	  to	  grow	  the	  tumors	  in	  the	  mouse	  and	  
they	  were	  seeing	  too	  much	  variability	  in	  the	  results.	  
(Ref 15)	  
Chemotherapeu/c	  agents	  are	  poisons	  that	  
signiﬁcantly	  weaken	  the	  pa/ent.	  (Ref 16)	  
They	  are	  used	  because	  cancer	  cells	  are	  ojen	  weaker	  
than	  healthy	  cells	  to	  certain	  chemicals	  and	  the	  goal	  is	  
to	  eradicate	  the	  cancer	  before	  killing	  the	  pa/ent.	  	  	  
Trea/ng	  a	  pa/ent	  with	  the	  wrong	  chemotherapeu/c	  
agent	  not	  only	  will	  not	  work,	  it	  will	  further	  weaken	  an	  
already	  seriously	  ill	  person.	  	  	  
However,	  colon	  cancer	  is	  a	  very	  aggressive	  cancer.	  	  
Thirty	  weeks	  can	  be	  too	  long	  to	  wait	  before	  star/ng	  







In	  a	  blind	  study	  using	  VBI’s	  technology,	  pa/ent	  tumors	  
were	  grown	  in	  HuBiogel™	  and	  treated	  with	  known	  
drugs	  along	  with	  control	  samples.	  	  	  
Neither	  Vivo	  Biosciences	  nor	  Champions	  Oncology	  
iden/ﬁed	  which	  samples	  were	  which.	  	  Vivo	  
Biosciences	  submi\ed	  the	  HuBiogel™	  test	  results	  to	  






In	  the	  very	  ﬁrst	  study	  performed,	  HuBiogel™	  
tests	  were	  correct	  in	  70-­‐80%	  of	  the	  cases,	  but	  it	  
only	  took	  2-­‐3	  weeks	  to	  get	  the	  results	  and	  not	  30	  
weeks.	  (Ref 17)	  
This	  speed	  can	  make	  a	  cri/cal	  diﬀerence	  for	  a	  pa/ent	  
suﬀering	  from	  colon	  cancer	  and	  other	  aggressive	  
cancers.	  	  	  
The	  goal	  now	  is	  to	  predict	  and	  achieve	  >90%	  accuracy	  
in	  2	  week	  analyses.	  	  Achieving	  this	  accuracy	  is	  where	  
VBI	  believes	  that	  space	  research	  could	  make	  the	  
diﬀerence.	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Scope	  of	  Case	  Study	  	  
ESO	  funds	  were	  limited	  to	  the	  ﬁrst	  step	  of	  
development	  of	  a	  commercial	  biotech	  ﬂight	  
inves/ga/on	  by	  a	  small	  company	  (Vivo	  Biosciences)	  
that	  had	  never	  conducted	  space	  research.	  	  	  
The	  company	  was	  chosen	  through	  an	  unsolicited	  
proposal	  that	  was	  technically	  reviewed	  for	  merit.	  	  It	  
was	  determined	  that	  the	  company	  was	  credible,	  at	  
the	  cupng	  edge	  of	  medically	  important	  research	  and,	  
if	  the	  space	  inves/ga/ons	  were	  successful,	  the	  
results	  would	  provide	  signiﬁcant	  public	  beneﬁts.	  	  	  
It	  was	  also	  determined	  that	  there	  were	  almost	  no	  
funding	  opportuni/es	  for	  this	  type	  of	  research.	  	  	  
One	  reason	  for	  ESO’s	  interest	  is	  that	  Vivo	  
Biosciences	  represents	  the	  kind	  of	  new	  high	  tech	  
small	  business	  community	  who	  might	  be	  both	  early	  
adopters	  and	  early	  successes	  in	  the	  ISS	  NaKonal	  
Laboratory	  and	  other	  commercial	  space	  plaborms,	  
like	  a	  SpaceX	  Dragon	  Lab	  or	  a	  Bigelow	  Space	  
Laboratory.	  
The	  speciﬁc	  technical	  objec/ve	  was	  to	  determine	  
whether	  exis/ng	  commercial	  oﬀ-­‐the-­‐shelf	  hardware	  
would	  work	  suﬃciently	  well	  to	  meet	  the	  VBI’s	  strin-­‐
gent	  culture	  requirements	  on	  the	  ground	  before	  
commipng	  to	  a	  space	  ﬂight	  project.	  	  	  
The	  hope	  is	  that	  space	  would	  oﬀer	  medically	  superior	  
results.	  	  	  If	  the	  cultures	  could	  not	  be	  grown	  ade-­‐
quately	  in	  the	  ﬂight	  hardware	  on	  the	  ground,	  there	  
would	  be	  no	  point	  in	  pursuing	  a	  ﬂight	  inves/ga/on.	  	  	  
Ajer	  the	  ini/al	  phase	  of	  the	  study	  was	  complete,	  the	  
intent	  was	  to	  provide	  this	  informa/on	  to	  CASIS,	  to	  
NASA’s	  Space	  Life	  and	  Physical	  Sciences	  Research	  and	  
Applica/ons	  Division,	  and	  other	  interested	  par/es	  for	  
their	  considera/on,	  however,	  ESO	  did	  not	  intend	  to	  






Speciﬁcally,	  ESO	  provided	  $50K	  to	  Vivo	  Biosciences	  to	  
document	  their	  experience	  as	  they	  worked	  with	  the	  
ﬂight	  equipment	  and	  support	  of	  a	  well-­‐established	  ISS	  
commercial	  ﬂight	  research	  services	  provider	  
(BioServe	  Space	  Technologies).	  	  	  
	  
The	  technical	  goal	  was	  to	  evaluate	  BioServe’s	  /ssue	  
culture	  hardware	  (BioCell)	  to	  determine	  if	  it	  would	  
support	  VBI’s	  unique	  needs	  for	  developing	  a	  be\er	  
cancer	  research	  tool	  (focused	  on	  colon	  cancer	  and	  
breast	  cancer,	  ini/ally).	  	  	  
	  
Technical	  success	  would	  be	  characterized	  by	  the	  
ability	  to	  grow,	  on	  the	  ground,	  well-­‐understood	  test	  
tumors	  in	  exis/ng	  commercial	  space	  ﬂight	  hardware	  
(Bioserve’s	  Biocell).	  	  	  
	  
The	  goal	  was	  to	  produce,	  in	  the	  ﬂight	  hardware,	  
tumors	  of	  the	  size	  and	  characterisKcs	  necessary	  for	  
scienKﬁcally	  valid	  results.	  	  This	  is	  the	  necessary	  tech-­‐







VBI HuBiogel™ plus 
human tumor cells in 
BioServe Space 
Technologies’ BioCell 
initiating $ight test. 
Image 8 
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From	  microbe	  to	  human,	  all	  life	  that	  we	  know	  begins	  with	  a	  single	  cell.	  	  Cells	  are	  the	  fundamental	  unit	  of	  life.	  	  When	  cells	  
mul/ply	  and	  assemble	  themselves	  into	  an	  organized	  structure,	  it	  is	  called	  a	  /ssue.	  	  Tissues	  assemble	  into	  organs.	  	  Organs	  
assemble	  into	  systems.	  	  Systems	  assemble	  into	  all	  of	  the	  unique	  mul/cellular	  creatures	  of	  Earth,	  including	  humans.	  The	  
process	  by	  which	  the	  type	  of	  cells	  in	  a	  /ssue	  or	  organ	  change	  is	  known	  as	  diﬀeren@a@on,	  and	  is	  an	  outcome	  sought	  from	  


















Cell	  culture	  is	  the	  complex	  process	  by	  which	  cells	  are	  
grown	  under	  controlled	  condi/ons,	  generally	  outside	  of	  
their	  natural	  environment	  (in	  vitro).	  	  	  	  
	  
Tissue	  culture	  is	  the	  complex	  process	  by	  which	  cells	  
taken	  from	  a	  body	  (in	  vivo	  cells)	  and	  placed	  in	  an	  
ar/ﬁcial	  environment	  (in	  vitro	  culture)	  are	  managed	  in	  
such	  a	  way	  as	  to	  cause	  the	  cells	  to	  associate,	  organize	  
and	  change	  (diﬀeren@ate)	  to	  form	  /ssues.	  	  (See Image 9)	

	  
Because	  they	  reduce	  misleading	  variables	  generated	  by	  
research	  in	  an	  en/re	  human	  being	  or	  animal	  model,	  
good	  /ssue	  and	  tumor	  cultures	  can	  signiﬁcantly	  reduce	  
the	  /me	  it	  takes	  to	  determine	  the	  cause	  of	  a	  disease,	  to	  
characterize	  how	  it	  progresses,	  as	  well	  as	  to	  reduce	  the	  
/me	  it	  takes	  to	  develop	  and	  test	  eﬀec/ve	  pharmacolog-­‐
ical	  solu/ons.	  	  Good	  cultures	  can	  accelerate	  research	  
progress	  by	  years,	  saving	  lives	  and	  millions	  of	  dollars	  in	  
the	  process.	  (Ref 19)	  
	  
The	  quality	  of	  a	  /ssue	  or	  tumor	  culture	  depends	  en-­‐
/rely	  on	  how	  well	  that	  culture	  mimics	  the	  dynamics	  of	  
cells	  and	  /ssues	  resident	  in	  three-­‐dimensional	  struc-­‐
tures	  (organs,	  /ssues,	  tumors)	  inside	  the	  body.	  (Ref 20)	

	  
Cells	  and	  /ssues	  react	  based	  on	  the	  physical,	  chemical	  
and	  biological	  signals	  in	  their	  environment.	  (Ref 21)	

	  
Cells	  are	  not	  smart,	  but	  they	  are	  highly	  adaptable.	  	  If	  
they	  are	  given	  the	  same	  environmental	  cues	  outside	  
the	  body	  (in	  vitro)	  that	  they	  receive	  inside	  the	  body	  (in	  
vivo),	  the	  cells	  will	  behave	  as	  if	  in	  they	  are	  s/ll	  part	  of	  
the	  pa/ent.	  	  	  If	  they	  are	  given	  diﬀerent	  environmental	  
cues,	  they	  will	  react	  in	  ways	  that	  are	  not	  medically	  









Cells	  and	  /ssues	  (including	  tumors)	  receive	  informa/on	  
from	  their	  en/re	  surface	  –	  top,	  sides,	  and	  bo\om.	  	  Cells	  
and	  /ssues	  also	  communicate	  with	  each	  other	  in	  
complex	  and	  subtle,	  but	  important,	  ways.	  	  	  
	  
The	  goal	  in	  /ssue	  cultures	  is	  to	  provide	  the	  right	  
environmental	  cues	  and	  manage	  the	  development	  
process	  in	  vitro	  over	  days	  and	  weeks	  so	  that	  cells	  and	  












Genes	  direct	  the	  assembly	  of	  par/cular	  proteins.	  	  We	  
develop	  from	  an	  egg	  to	  a	  human	  by	  the	  produc/on	  of	  
speciﬁc	  proteins,	  our	  health	  is	  determined	  by	  the	  
produc/on	  of	  speciﬁc	  proteins,	  and	  we	  die	  because	  of	  
the	  presence	  or	  absence	  of	  speciﬁc	  proteins.	  	  	  
	  
The	  genome	  is	  a	  the	  complete	  set	  of	  genes	  in	  an	  organ-­‐
ism,	  and	  each	  cell	  contains	  a	  full	  copy	  of	  its	  genome.	  	  	  
	  
Diﬀeren/a/on	  is	  caused	  by	  the	  par/cular	  combina/on	  
of	  genes	  that	  are	  turned	  on	  (expressed)	  or	  turned	  oﬀ	  
(repressed)	  in	  each	  cell.	  (Ref 22)	

	  
The	  speciﬁc	  pa\ern	  of	  genes	  expressed	  or	  repressed	  
dictates	  each	  cell’s	  shape	  and	  func/on,	  as	  shown	  in	  
image	  9.	  	  
Image: 9.  Cell aggregates in culture  diﬀerentiating into tissues  
Gravity	  causes	  cells	  and	  /ssues	  that	  have	  been	  removed	  
from	  the	  body	  and	  placed	  into	  petri	  dishes	  ﬁlled	  with	  a	  
nutrient	  solu/on	  to	  se\le	  to	  the	  bo\om.	  	  The	  layer	  of	  cells	  
in	  direct	  contact	  with	  the	  bo\om	  of	  petri	  dish	  change	  
inappropriately	  in	  response	  to	  contact	  with	  the	  ﬂat	  
surface.	  	  This	  error	  propagates	  to	  the	  cells	  above	  them,	  









Scien/sts	  know	  this,	  so	  in	  an	  a\empt	  to	  overcome	  the	  
extreme	  limita/ons	  of	  2-­‐D	  /ssue	  cultures,	  they	  began	  
suspending	  the	  cells	  in	  a	  nutrient	  solu/on,	  using	  a	  s/rrer	  
and	  small	  mixing	  motor	  to	  keep	  the	  cells	  from	  se\ling	  to	  
the	  bo\om.	  	  Unfortunately,	  as	  the	  3-­‐D	  /ssue	  aggregates	  
get	  larger,	  more	  mechanical	  energy	  is	  required	  to	  maintain	  
the	  /ssues	  in	  suspension.	  	  About	  the	  /me	  the	  /ssues	  
become	  useful	  to	  medical	  research,	  so	  much	  mechanical	  
energy	  is	  required	  to	  keep	  them	  suspended	  that	  the	  sheer	  
and	  	  turbulence	  forces	  generated	  by	  the	  motor	  causes	  	  the	  












The	  major	  advance	  in	  this	  area	  came	  from	  NASA	  JSC’s	  
inven/on	  of	  the	  Rota/ng	  Wall	  Vessel,	  a	  spinoﬀ	  now	  being	  
sold	  by	  Synthecon	  and	  marketed	  worldwide	  and	  is	  the	  
industry	  standard	  in	  certain	  types	  of	  research,	  including	  
Vivo	  Biosciences’.	  (Ref 26)	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This	  process	  of	  gene	  expression	  is	  regulated	  by	  factors	  
from	  both	  within	  the	  cell	  (intrinsic)	  and	  outside	  cells	  
(extrinsic),	  and	  the	  interplay	  between	  these	  cues	  and	  
the	  genome	  aﬀects	  essen/ally	  all	  processes	  that	  occur	  
during	  embryonic	  development	  and	  adult	  life.	  (Ref 23)	  
	  
Cell-­‐extrinsic	  factors	  that	  regulate	  expression	  include	  
environmental	  cues,	  such	  as	  small	  molecules,	  
nutrients,	  toxins,	  temperature,	  oxygen,	  …	  and	  gravity.	  	  
These	  cues	  can	  originate	  from	  other	  cells	  within	  the	  
organism,	  or	  they	  can	  come	  from	  the	  organism's	  
environment.	  (Ref 24)	  
	  
Within	  the	  organism,	  cells	  communicate	  with	  each	  
other	  by	  sending	  and	  receiving	  proteins,	  also	  known	  
as	  growth	  factors,	  morphogens,	  cytokines,	  or	  sig-­‐
naling	  molecules.	  	  Receipt	  of	  these	  signaling	  mole-­‐
cules	  triggers	  signaling	  cascades	  within	  the	  cells	  that	  
ul/mately	  cause	  semi-­‐permanent	  changes	  in	  the	  
expression	  of	  genes.	  (Ref 25)	  
	  
Such	  changes	  in	  gene	  expression	  can	  include	  turn-­‐	  	  	  
ing	  genes	  completely	  on	  or	  oﬀ,	  or	  just	  slightly	  tweak-­‐
ing	  the	  level	  of	  transcript	  produced.	  This	  process	  reg-­‐
ulates	  a	  vast	  number	  of	  cell	  behaviors.	  
	  
To	  produce	  /ssue	  cultures	  that	  mimic	  what	  happens	  
in	  the	  body,	  scien/sts	  must	  provide	  an	  environment	  
that	  accurately	  simulates	  the	  environmental	  cues	  the	  
/ssues	  received	  in	  vivo.	  	  The	  be\er	  this	  is	  done,	  the	  
more	  useful	  the	  cultures	  are	  for	  medical	  research.	  
	  
The	  problem	  is	  that	  organs	  and	  /ssues	  in	  the	  body	  
support	  each	  other	  in	  three	  dimensions.	  	  When	  they	  
are	  removed	  from	  the	  body	  and	  put	  in	  ar/ﬁcial	  
culture	  systems,	  gravity	  prevents	  the	  normal	  









ESO	  Commercial	  Microgravity	  Case	  Study	  1	  –	  Novice	  Users	  –	  A	  Small	  Business	  Perspective	  
Science	  of	  3-­‐D	  Tissue	  Cultures	  
18	  
The	  basic	  design	  of	  a	  Rotary	  Cell	  Culture	  system	  (shown	  lej)	  is	  a	  cylindrical	  vessel	  called	  a	  
bioreactor	  that	  is	  turned	  on	  its	  side	  and	  rotated	  using	  an	  electric	  motor	  (ini/ally	  an	  electric	  
drill).	  	  As	  long	  as	  the	  cylinder	  is	  completely	  ﬁlled	  with	  nutrient	  ﬂuid,	  the	  cells	  remain	  
suspended	  and	  the	  low	  shear	  and	  turbulence	  environment	  produced	  higher	  quality	  /ssues	  





The	  /ssues	  and	  tumors	  produced	  in	  the	  Rota/ng	  Wall	  
Vessel	  are	  larger	  than	  those	  produced	  by	  any	  other	  
method,	  but	  even	  so,	  gravity	  limits	  the	  size	  of	  the	  /ssues	  
to	  about	  1-­‐2	  mm,	  which	  is	  s/ll	  too	  small	  to	  inves/gate	  
many	  of	  the	  issues	  related	  to	  cancer,	  infec/ous	  diseases,	  
and	  organ	  diseases.	  (Ref 28)	  
	  
Microgravity	  does	  three	  things.	  
	  
First,	  in	  suspension	  culture,	  	  shear	  is	  directly	  propor/onal	  
to	  gravity.	  Reduc/on	  of	  gravity	  allows	  suspension	  cultures	  








available	  in	  space	  (or	  magne/c	  levita/on	  but	  then	  the	  ﬂux	  
complicates	  things).	  	  Under	  these	  condi/ons	  cells	  of	  
diﬀerent	  densi/es	  and	  sizes	  can	  be	  collocated.	  	  
	  
Second,	  	  convec/on	  is	  reduced	  in	  space,	  which	  is	  espe-­‐
cially	  important	  for	  gas	  and	  other	  nutrient	  exchange,	  and	  
allows	  study	  of	  redox	  states	  not	  available	  in	  any	  other	  
model.	  	  
	  
Third,	  there	  may	  be	  direct	  eﬀects	  of	  microgravity	  on	  the	  
cell	  via	  microtubules	  or	  some	  other	  gravity	  sensor.	  This	  is	  
a	  possibility	  that	  is	  s/ll	  debated	  and	  controversial.	  	  
	  
So,	  in	  space,	  the	  gravita-­‐
/onal	  limita/ons	  to	  the	  
size	  of	  /ssue	  cultures	  are	  
removed.	  	  	  
	  
Then	  the	  challenge	  is	  to	  
manage	  the	  rest	  of	  the	  
environmental	  param-­‐
eters	  well	  enough	  in	  
space	  to	  take	  advantage	  
of	  the	  unconstrained	  
opportuni/es	  for	  /ssue	  
and	  tumor	  growth.	  	  The	  
goal	  is	  to	  produce	  higher	  
quality,	  not	  just	  larger,	  
/ssues	  and	  tumors.	  	  	  
	  
This	  will	  take	  a	  great	  deal	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Results	  and	  Findings	  
Summary	  of	  Research	  Strategy:	  	  	  
Vivo	  Biosciences	  selected	  representa/ve	  samples	  for	  
study	  (Colon	  tumor:	  HT29	  and	  Breast	  tumor:	  MDA231)	  
and	  test	  protocols	  were	  established.	  (Ref 28)	  
The	  test	  would	  require	  successfully	  managing	  the	  
culture	  condi/ons	  and	  ﬁxa/on	  strategies	  for	  4-­‐6	  weeks	  
in	  the	  ﬂight	  hardware	  under	  an/cipated	  space	  ﬂight	  
condi/ons.	  	  	  
From	  this,	  Vivo	  Biosciences	  would	  determine	  the	  
adequacy	  of	  tumor	  growth	  and	  func/on	  in	  the	  BioCell	  
using	  imaging	  and	  biochemical	  analyses.	  	  	  
The	  results	  would	  determine	  whether	  a	  ﬂight	  
inves/ga/on	  had	  a	  high	  probability	  of	  yielding	  new	  
important	  insights	  for	  project	  improvement.	  	  
Ajer	  six	  months,	  Vivo	  Biosciences	  concluded	  that	  
some	  but	  not	  all	  their	  technical	  goals	  could	  be	  met	  
because	  the	  BioCell	  chamber	  was	  too	  small.	  	  	  
The	  most	  cri/cal	  technical	  goal	  was	  to	  produce	  larger	  
3-­‐D	  tumors	  in	  HuBiogel™	  than	  could	  be	  grown	  on	  the	  
ground	  and	  with	  medically	  important	  features	  that	  
could	  not	  be	  achieved	  in	  smaller	  /ssues.	  	  The	  BioCell	  
Chamber	  was	  too	  small	  to	  achieve	  this.	  	  	  
However,	  they	  did	  determine	  that	  there	  were	  no	  
fundamental	  biocompa/bility	  issues	  with	  the	  BioCell	  
materials;	  that	  they	  could	  manage	  the	  /ssue	  growth	  





and	  that	  the	  necessary	  protocols	  could	  be	  
automated	  and	  would	  eﬀec/vely	  ﬁx	  samples	  to	  
produce	  scien/ﬁcally	  valid	  samples	  for	  posylight	  
analyses.	  
	  
Once	  hardware	  modiﬁca/ons	  are	  made	  and	  ﬂight-­‐
tested	  (BioServe	  has	  a	  manifested	  ﬂight	  test	  on	  
Dragon	  during	  fall	  2013),	  the	  Vivo	  Biosciences	  
biocompa/bility	  study	  would	  need	  to	  be	  repeated	  in	  
order	  to	  conﬁrm	  that	  the	  redesigned	  hardware	  will	  
meet	  the	  company’s	  technical	  requirements.	  	  	  
	  
For	  these	  reasons,	  this	  inves/ga/on	  s/ll	  remains	  in	  
the	  ﬁrst	  step	  of	  development	  and	  provides	  the	  ﬁrst	  





Commercial	  biotech	  research	  will	  seek	  speciﬁc	  research	  
outcomes	  that	  are	  likely	  to	  require	  changes	  in	  ﬂight	  
hardware.	  	  	  
	  
Even	  the	  iniKal	  test	  and	  iteraKon	  of	  a	  ﬂight	  experiment	  
costs	  so	  much	  Kme	  and	  money	  that	  most	  	  small	  
companies	  will	  be	  unable	  to	  fund	  ﬂight	  research	  without	  
help	  from	  the	  government	  or	  other	  angel	  investor.	  	  	  
	  
However,	  these	  small	  companies	  are	  oden	  the	  
pathﬁnders	  for	  new	  capabiliKes	  in	  high	  tech	  industries.	  	  	  
	  
This	  is	  the	  kind	  of	  community	  that	  can	  pioneer	  
important	  new	  uses	  for	  the	  ISS	  NaKonal	  Laboratory,	  
serving	  both	  the	  naKon	  and	  NASA’s	  interest	  well.	  
	  
19	  
Research	  Outcome	  Sought:	  	  Vivo	  Biosciences	  wants	  to	  know	  as	  soon	  as	  
possible	  whether	  using	  their	  product	  in	  space	  will	  yield	  knowledge	  
products	  that	  result	  in	  increased	  accuracy,	  predicKon	  and	  insight	  in	  any	  
of	  the	  types	  of	  cancer	  research	  that	  they	  support.	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Results	  and	  Findings	  
From	  the	  Emerging	  Space	  Oﬃce’s	  (ESO)	  perspec/ve,	  
success	  in	  this	  study	  was	  characterized	  by	  insights	  
obtained	  from	  the	  experience	  of	  a	  small	  company,	  
unfamiliar	  with	  spaceﬂight,	  as	  they	  a\empted	  to	  
develop	  a	  successful	  space	  ﬂight	  inves/ga/on,	  
especially	  those	  that	  can	  be	  applied	  to	  other	  similar	  
commercial	  ventures.	  	  This	  goal	  was	  met.	  	  	  
Of	  the	  $50K	  ESO	  funding	  	  (Ref 29):	  
  $28K	  supported	  the	  Vivo	  Biosciences	  PI	  and	  a	  
part	  /me	  temporary	  research	  assistant	  for	  
prepara/on	  and	  analyses;	  	  
  $11K	  went	  to	  BioServe	  Space	  Technologies	  for	  
leasing	  the	  ﬂight	  test	  unit	  and	  design	  services;	  
and	  	  
  $11K	  went	  for	  /ssue	  culture	  supplies	  and	  
reagents	  used	  to	  grow	  the	  /ssues.	  	  	  
The	  result	  is	  that	  the	  inves/ga/on	  is	  s/ll	  not	  ready	  to	  
ﬂy	  because	  the	  ﬂight	  hardware	  is	  not	  conﬁgured	  for	  
the	  speciﬁc	  research	  outcome	  sought	  by	  the	  
customer.	  	  
Flight	  accommoda/ons	  as	  currently	  conﬁgured	  are	  
not	  customer-­‐friendly	  for	  novices,	  although	  BioServe	  
Space	  Technologies	  provided	  excellent	  support	  to	  
Vivo	  Biosciences	  throughout	  the	  study.	  	  	  
It	  is	  because	  of	  the	  quality	  of	  BioServe’s	  
support	  and	  because	  Vivo	  Biosciences	  
currently	  does	  not	  have	  beher	  opKons	  than	  
space	  for	  product	  improvement	  that	  VBI	  is	  
willing	  to	  conKnue	  working	  towards	  a	  ﬂight	  








If	  either	  BioServe’s	  support	  is	  unavailable	  or	  another	  
op/on	  for	  improved	  tumor	  quality	  arises,	  it	  is	  highly	  
unlikely	  that	  Vivo	  Biosciences	  would	  s/ll	  pursue	  ﬂight	  
research.	  
	  
The	  Case	  Study	  illuminated	  a	  number	  of	  important	  
exis/ng	  capabili/es	  and	  exemplars	  useful	  to	  a	  com-­‐
munity	  of	  poten/al	  commercial	  customers,	  such	  as	  :	  	  
	  
  The	  existence	  of	  a	  con/nually	  opera/ng	  crewed	  
playorm	  like	  the	  ISS,	  	  
  The	  immediate	  availability	  of	  ﬂight	  hardware,	  	  
  Regular	  ﬂights	  for	  payload	  delivery	  
  Sample	  return	  on	  SpaceX’s	  Dragon,	  	  
  The	  services	  of	  guides	  like	  BioServe;	  	  
The	  Case	  Study	  also	  revealed	  issues	  that	  may	  be	  
common	  in	  3-­‐D	  /ssue	  research	  in	  space	  in	  general,	  
and,	  in	  par/cular,	  with	  small	  companies	  a\emp/ng	  
medically	  oriented	  commercial	  research	  in	  space.	  	  For	  
example:	  
	  
  Unfamiliar	  environments,	  	  
  Long	  lead	  /mes,	  high	  costs	  of	  and	  long	  delays	  
between	  itera/ons,	  	  
  Lack	  of	  seed	  funding.	  	  	  
	  	  
If	  uncorrected,	  some	  of	  these	  issues	  are	  serious	  
enough	  to	  preclude	  or	  at	  least	  signiﬁcantly	  inhibit	  
the	  parKcipaKon	  of	  paying	  customers	  on	  the	  ISS	  or	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Results	  and	  Findings	  
continued 
The	  Case	  Study	  made	  clear	  that	  space	  research	  
for	  a	  commercial	  company	  is	  a	  very	  high-­‐risk	  
strategy,	  even	  if	  the	  potenKal	  payoﬀ	  is	  high.	  	  	  
	  
Funding	  opportuniKes	  both	  inside	  and	  outside	  
of	  NASA	  	  for	  this	  type	  of	  research	  are	  few.	  	  	  
When	  the	  VBI	  Case	  Study	  started,	  it	  was	  not	  known	  
whether	  tumors	  could	  grow	  well	  enough	  in	  exis/ng	  
space	  ﬂight	  hardware	  to	  make	  a	  space	  inves/ga/on	  
worth	  the	  money,	  /me,	  and	  company	  resources	  
that	  the	  a\empt	  would	  require.	  	  	  	  
	  
It	  is	  s/ll	  not	  known,	  but	  ini/al	  results	  are	  promising.	  	  
	  
But	  even	  if	  the	  ground-­‐based	  biocompa/bility	  study	  
were	  successful,	  it	  would	  s/ll	  not	  be	  known	  
whether	  this	  inves/ga/on	  would	  be	  successful	  in	  
space	  without	  doing	  the	  experiment	  in	  microgravity.	  	  	  
	  
However,	  because	  there	  were	  no	  cri/cal	  ﬂaws	  and	  
because	  the	  hardware	  issues	  are	  being	  corrected,	  
all	  par/cipants	  are	  s/ll	  interested	  in	  re-­‐doing	  the	  
biocompa/bility	  test,	  at	  a	  minimum.	  
	  
It	  is	  recommended	  that	  NASA	  support	  the	  next	  
itera/on	  and	  track	  the	  next	  stage	  of	  the	  company’s	  
experience	  because	  whether	  VBI’s	  research	  
objec/ves	  are	  met	  or	  not,	  VBI’s	  experience	  will	  oﬀer	  
valuable	  insights	  NASA	  and	  the	  commercial	  space	  
community.	  	  	  
	  
	  
Terrestrial	  labs	  do	  not	  have	  to	  manage	  launch	  
stresses,	  unwanted	  and	  non-­‐intui/ve	  eﬀects	  of	  
microgravity,	  crew	  /me	  priori/es,	  re-­‐entry	  
stresses,	  and	  post-­‐ﬂight	  recovery	  delays.	  	  	  	  
	  
Space	  laboratory	  research	  is	  a	  skill	  that	  takes	  years	  
and	  mul/ple	  hands-­‐on	  ﬂight	  experiences	  to	  
develop.	  	  Novice	  ﬂight	  inves/gators	  need	  guides.	  
	  
In	  biotech,	  no	  one	  does	  research	  on	  the	  ground	  the	  way	  it	  has	  to	  be	  done	  
in	  space.	  	  	  
Laboratory	  research	  in	  microgravity	  is	  
so	  diﬀerent	  from	  anything	  a	  typical	  
laboratory	  scienGst	  would	  experience	  
on	  Earth	  that	  it	  is	  akin	  to	  pursuing	  a	  
graduate	  degree	  in	  a	  new	  technical	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BioServe	  was	  a	  proac/ve	  and	  suppor/ve	  technical	  and	  
scien/ﬁc	  partner	  in	  the	  development	  of	  the	  research.	  	  
They	  provided	  a	  signiﬁcant	  amount	  of	  useful	  guidance	  
to	  Vivo	  Biosciences	  that	  shorted	  their	  learning	  cycle.	  	  	  
	  
This	  is	  the	  result	  of	  BioServe's	  long	  and	  successful	  
experience	  in	  ﬂying	  pioneer	  biotech	  inves/ga/ons	  in	  
space	  and	  their	  experience	  in	  selec/ng	  materials	  that	  
minimize	  biocompa/bility	  issues.	  They	  are	  accustomed	  
to	  working	  with	  novice	  commercial	  inves/gators.	  	  
	  
The	  hardware	  modiﬁca/ons	  needed	  for	  the	  VBI	  ﬂight	  
study	  are	  rela/vely	  minor.	  	  This	  makes	  the	  experiment	  
s/ll	  worth	  pursuing.	  
	  
The	  feedback	  from	  Vivo	  Biosciences	  and	  other	  poten/al	  
customers	  helped	  BioServe	  decide	  to	  modify	  their	  ﬂight	  
hardware	  to	  enable	  larger	  3-­‐D	  /ssue	  and	  organ	  growth.	  	  	  
	  
The	  modiﬁed	  ﬂight	  hardware	  will	  be	  ﬂown	  on	  Dragon	  to	  
ISS	  in	  the	  fall	  2013	  for	  tes/ng.	  	  	  
The	  role	  of	  a	  mentor	  or	  guide	  who	  provides	  a	  bridge	  between	  the	  needs	  of	  a	  novice	  ﬂight	  
invesKgator	  and	  the	  accommodaKons	  and	  constraints	  of	  space	  ﬂight	  is	  the	  single	  most	  essenKal	  
element	  in	  crading	  a	  successful	  research	  experience	  for	  new	  entrants	  into	  space	  laboratories.	  	  
The	  Case	  Study	  became	  a	  catalyst	  for	  developing	  
improved	  capabili/es	  based	  on	  customer	  needs,	  which	  is	  
another	  feature	  of	  a	  commercial	  venture:	  @mely	  product	  
improvement	  based	  on	  customer	  feedback.	  
	  
That	  the	  Interna/onal	  Space	  Sta/on	  (ISS)	  is	  available	  for	  
research	  and	  that	  SpaceX	  Dragon	  can	  provide	  the	  cri/cal	  
return	  of	  samples	  to	  earth	  as	  well	  as	  payload	  trans-­‐
porta/on	  to	  the	  ISS	  were	  all	  essen/al	  to	  Vivo	  Biosciences	  
research	  goals.	  	  
	  
Commercial	  companies	  who	  contemplate	  using	  space	  to	  
improve	  their	  product	  lines	  are	  agnosKc	  about	  which	  
vehicle	  to	  use.	  	  	  
	  
They	  are	  only	  interested	  in	  selecKng	  the	  strategy	  that	  
delivers	  the	  highest	  value	  at	  the	  lowest	  cost.	  	  	  
	  
For	  these	  reasons,	  mulKple	  ﬂight	  research	  plaborms	  are	  
mutually	  synergisKc.	  	  	  	  As	  an	  example,	  for	  VBI’s	  







Future	  mulK-­‐plaborm	  synergies	  can	  
amplify	  the	  opportuniKes,	  	  value	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
and	  customer	  base	  for	  each	  vehicle.	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For	  example,	  ajer	  BioServe	  ﬂies	  its	  modiﬁed	  
hardware	  and	  conﬁrms	  performance	  (approx-­‐
imately	  6	  months	  ajer	  this	  study	  was	  completed),	  
Vivo	  Biosciences	  will	  again	  need	  to	  test	  their	  tumor	  
system	  on	  the	  ground	  in	  the	  modiﬁed	  hardware.	  	  	  
	  	  
The	  cost	  and	  /me	  to	  do	  the	  next	  itera/on	  for	  
biocompa/bility	  tes/ng	  for	  space	  ﬂight	  are	  
expected	  to	  be	  roughly	  the	  same	  as	  in	  the	  ﬁrst	  
study.	  	  	  
	  
Only	  if	  the	  ground	  tests	  are	  successful	  the	  second	  
/me	  can	  the	  ﬂight	  phase	  commence,	  no	  earlier	  
than	  6	  months	  later.	  	  	  Then	  another	  set	  of	  
anomalies	  is	  likely	  to	  be	  encountered	  in	  space	  that	  
requires	  adjustments	  to	  be	  made	  and	  the	  




Laboratory	  research	  is	  iteraKve	  and	  the	  ﬁrst	  steps	  oden	  involve	  calibraKng	  
equipment	  and	  reagents	  before	  the	  actual	  research	  begins.	  	  This	  is	  especially	  true	  
for	  spaceﬂight.	  	  While	  calibraKon	  is	  a	  minor	  step	  for	  a	  terrestrial	  lab,	  it	  is	  much	  more	  
diﬃcult	  and	  takes	  much	  longer	  both	  in	  space	  and	  in	  preparing	  for	  space.	  	  	  
It	  I	  almost	  certain	  that	  this	  process	  will	  need	  to	  
be	  repeated	  mul/ple	  /mes	  in	  space	  before	  a	  
breakthrough	  or	  even	  an	  insight	  is	  achieved.	  	  
	  	  
One	  thing	  is	  clear.	  	  Vivo	  Biosciences,	  as	  a	  small	  
business,	  is	  highly	  unlikely	  to	  be	  able	  to	  aﬀord	  
to	  pay	  for	  all	  of	  the	  R&D	  it	  needs	  to	  achieve	  a	  
successful	  outcome	  from	  ﬂight	  research	  
without	  outside	  support.	  	  	  
	  
Yet	  this	  kind	  of	  research	  could	  reveal	  important	  
new	  insights	  into	  what	  is	  s/ll	  one	  of	  humanity's	  
most	  intractable	  diseases.	  	  	  
	  
Unfortunately,	  exploratory	  research,	  which	  
describes	  the	  Vivo	  Biosciences	  ﬂight	  
inves/ga/on,	  has	  far	  fewer	  places	  to	  go	  for	  
funding	  than	  more	  mature	  research	  ventures.	  	  	  
	  
In	  some	  ways,	  this	  is	  what	  
makes	  commercial	  space	  
laboratory	  research	  and	  
commercial	  space	  services	  
such	  natural	  partners:	  	  both	  
beneﬁt	  from	  ﬂight	  frequency	  
to	  realize	  proﬁts.	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Government	  support	  of	  this	  type	  of	  invesKgaKon	  is	  not	  just	  important,	  but	  enabling.	  
It	  is	  clear	  that	  given	  the	  size	  of	  their	  company	  
and	  the	  demands	  on	  their	  resources	  to	  support	  
their	  paying	  customers,	  a	  small	  company	  like	  
Vivo	  Biosciences	  cannot	  self-­‐fund	  research	  
ventures	  in	  space.	  	  	  
	  
It	  is	  simply	  too	  expensive,	  takes	  too	  long,	  and	  
requires	  too	  much	  specialized	  knowledge.	  
	  
Whether	  Vivo	  Biosciences	  can	  implement	  its	  
inves/ga/on	  series	  soon	  enough,	  cheaply	  
enough,	  and	  well	  enough	  to	  meet	  their	  needs,	  
s/ll	  remains	  to	  be	  seen.	  	  	  
	  
	  
For	  any	  company,	  /me	  is	  money.	  	  	  
	  
During	  the	  six	  months	  that	  Vivo	  Biosciences	  
conducted	  this	  study,	  it	  completed	  two	  landmark	  
studies	  for	  paying	  customers,	  which	  illustrates	  
another	  point.	  	  	  
	  
The	  priority	  of	  companies,	  especially	  small	  
companies,	  must	  be	  to	  support	  their	  paying	  
customers	  while	  the	  space	  ﬂight	  inves/ga/ons	  
are	  being	  developed.	  	  Ojen	  they	  won’t	  have	  the	  
resources	  to	  do	  both	  with	  internal	  funds.	  
	  	  
It	  will	  be	  another	  six	  months	  before	  the	  modiﬁed	  
hardware	  completes	  its	  ﬂight	  test.	  	  The	  next	  
biocompa/bility	  test	  will	  take	  another	  2-­‐4	  
months	  at	  best.	  	  	  
	  
If	  all	  of	  that	  works,	  then	  Vivo	  Biosciences	  could	  
be	  manifested	  for	  ﬂight	  6	  months	  later,	  assuming	  
that	  they	  are	  selected	  for	  funding.	  	  	  
	  
The	  amount	  of	  /me	  it	  takes	  to	  do	  a	  ﬂight	  
inves/ga/on	  (months	  to	  years)	  is	  signiﬁcantly	  out	  
of	  scale	  with	  a	  commercial	  laboratory	  inves-­‐
/ga/on	  on	  Earth,	  which	  measures	  projects	  in	  
days	  to	  weeks.	  
	  
Vivo	  Biosciences	  believes	  that	  removing	  gravity	  to	  
obtain	  larger,	  be\er-­‐quality	  tumors	  is	  one	  of	  the	  
few,	  and	  perhaps	  the	  best,	  op/on	  it	  has	  for	  
improving	  research	  outcomes	  with	  their	  product.	  	  	  




Image  16: When Vivo Biosciences investigation is ready to $y, the 
experiment will be conducted in BioServe’s Commercial Generic 
Bioprocessing Apparatus (CGBA) shown here on the ISS. 
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NaKonally,	  there	  are	  insuﬃcient	  funds	  for	  this	  type	  of	  early	  stage	  exploratory	  
applicaKons	  research	  that	  invesKgates	  promising	  but	  unproven	  microgravity	  
techniques	  and	  addresses	  a	  terrestrial	  versus	  space	  need.	  
The	  Center	  for	  the	  Advancement	  of	  Science	  in	  Space	  
(CASIS)	  is	  the	  most	  appropriate	  funding	  source	  for	  this	  
kind	  of	  work,	  but	  they	  have	  a	  very	  low	  research	  
budget	  for	  the	  scope	  of	  ﬂight	  ac/vi/es	  in	  their	  
poryolio.	  	  	  However,	  even	  CASIS	  prefers	  more	  mature	  
inves/ga/ons	  to	  support	  with	  their	  limited	  research	  
dollars.	  
	  
Exploratory	  research	  that	  is	  high	  risk	  (it	  probably	  
won’t	  work	  right	  way)	  and	  high	  payoﬀ	  (but	  it	  is	  a	  
breakthrough	  if	  it	  does)	  needs	  more	  support.	  	  	  
	  
Funding	  for	  this	  type	  of	  research	  is	  usually	  in	  the	  
purview	  of	  the	  government	  and	  angel	  investors.	  	  	  
Even	  corporate	  IRAD	  usually	  won’t	  support	  it.	  	  	  
	  
And	  a	  small	  business	  like	  Vivo	  Biosciences	  can’t	  aﬀord	  
to	  self-­‐fund	  a	  lengthy	  and	  expensive	  ﬂight	  
inves/ga/on	  even	  if	  they	  were	  conﬁdent	  that	  it	  would	  
work.	  
	  
Yet	  exploratory	  research	  is	  where	  revolu/onary	  break-­‐
throughs	  ojen	  begin.	  	  	  
	  
	  
Once	  a	  company	  has	  determined	  that	  their	  product	  
development	  is	  limited	  by	  gravity,	  the	  next	  step	  is	  to	  
determine	  whether	  any	  funding	  opportuni/es	  exist	  to	  
support	  its	  development.	  	  	  
	  
In	  this	  economy,	  even	  large	  corpora/ons	  are	  limi/ng	  
their	  high	  risk	  high	  payoﬀ	  IRAD	  investments.	  	  Small	  
companies	  usually	  can’t	  aﬀord	  them	  at	  all.	  
	  	  
Successful	  mature	  research	  that	  has	  demonstrated	  
desirable	  results	  for	  high	  priority	  medical	  problems	  
and	  has	  a	  clear	  hypothesis	  to	  be	  tested	  has	  many	  
opportuni/es	  to	  compete	  for	  funding.	  	  	  
	  
Pharmaceu/cal	  companies,	  philanthropic	  organ-­‐
iza/ons,	  some/mes	  venture	  capitalists	  as	  well	  as	  
government,	  are	  willing	  to	  help	  an	  obviously	  
promising	  and	  medically	  important	  technology	  to	  
market.	  	  And	  they	  should.	  	  This	  is	  a	  good	  investment.	  
	  
However,	  exploratory	  applica/ons	  R&D,	  like	  that	  
proposed	  by	  Vivo	  Biosciences,	  is	  at	  the	  earliest	  stages	  
of	  credible	  research,	  ojen	  too	  immature	  for	  even	  
basic	  research	  funding.	  	  	  
	  
NIH	  funds	  almost	  no	  research	  for	  space	  applica/ons.	  	  	  
	  
NASA’s	  Space	  Life	  and	  Physical	  Sciences	  Research	  
Program	  funds	  basic	  research	  but	  not	  applied	  
research	  for	  commercial	  terrestrial	  market.	  	  	  
	  
NASA’s	  Biomedical	  Research	  Program	  is	  focused	  on	  







“A	  reinvented	  business	  model	  won't	  
change	  what	  is	  fundamental:	  Higher	  
pipeline	  produc@vity	  in	  the	  form	  of	  new	  
patented	  products	  is	  s@ll	  the	  best	  source	  
of	  future	  proﬁts.”	  	  30	  
	  
PharmaExec.	  Com	  Jan.	  1.	  2012	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Conclusion	  
	  
Space	  oﬀers	  potenKally	  important	  new	  opportuniKes	  for	  commercial	  R&D	  that	  
could	  result	  in	  signiﬁcant	  public	  beneﬁts.	  	  But	  …	  
The	  government	  in	  general	  and	  NASA	  in	  par/cular	  can	  
play	  a	  key	  role	  in	  the	  development	  of	  this	  emerging	  
ﬁeld.	  	  	  
	  
In	  fact,	  if	  the	  government	  does	  not	  help	  this	  new	  
ﬁeld	  of	  laboratory	  sciences	  to	  grow,	  it	  is	  unlikely	  to	  
develop	  the	  criKcal	  mass	  of	  talent	  and	  ideas	  
necessary	  to	  achieve	  breakthroughs	  that	  can	  yield	  a	  
beher	  return	  on	  the	  taxpayers’	  investments.	  	  The	  ISS	  
and	  commercial	  space	  synergy	  is	  capable	  of	  
delivering	  more	  value.	  
	  
However,	  it	  will	  take	  more	  resources	  than	  are	  
currently	  being	  allocated	  to	  exploratory	  research	  -­‐-­‐	  
and	  not	  by	  realloca/ng	  funds	  from	  other	  ISS	  research	  
eﬀorts.	  The	  current	  research	  eﬀorts	  are	  synergis/c	  
with	  and	  inspire	  new	  exploratory	  research	  applica-­‐
/ons.	  	  	  The	  investment	  pool	  needs	  to	  grow,	  not	  be	  
redistributed.	  
	  
Breakthroughs	  will	  also	  take	  more	  opportuni/es	  to	  
learn	  and	  reﬁne	  strategies	  in	  space.	  	  	  
	  
The	  necessity	  of	  faster	  itera/on	  will	  require	  a	  more	  
user-­‐friendly	  set	  of	  policies	  and	  protocols	  (for	  both	  the	  
customer	  and	  for	  the	  NASA	  or	  commercial	  ﬂight	  
services	  providers)	  that	  accommodates	  the	  needs	  and	  
pressures	  of	  America’s	  innova/ve	  high	  tech	  
businesses	  and	  the	  requirements	  and	  challenges	  of	  
safely	  managing	  inves/ga/ons	  in	  space.	  	  	  
	  
These	  are	  not	  easy	  challenges,	  but	  the	  potenGal	  
payoﬀ	  is	  worth	  the	  eﬀort	  and	  the	  investment.	  	  
It	  will	  take	  the	  companies	  a	  signiﬁcant	  amount	  of	  
prac/ce	  in	  space	  to	  achieve	  the	  necessary	  research	  
outcomes	  reliably	  and	  predictably.	  	  	  
	  
Because	  of	  the	  uncertain/es	  inherent	  in	  ﬂight	  
inves/ga/ons,	  the	  expecta/on	  that	  the	  ISS	  Na/onal	  
Lab	  will	  a\ract	  a	  large	  number	  of	  paying	  customers	  
under	  the	  current	  condi/ons	  (high	  start-­‐up	  costs,	  
unfamiliar	  procedures,	  lengthy	  development	  /mes,	  
high	  risk	  of	  insuﬃcient	  outcome	  and	  long	  delays	  
between	  itera/ons)	  is	  unrealis/c.	  	  	  
	  
It	  will	  take	  more	  seed	  funding	  by	  the	  government,	  
CASIS,	  or	  other	  angel	  investors,	  because	  few,	  if	  any,	  
small	  biotech	  companies	  like	  Vivo	  Biosciences	  can	  
aﬀord	  to	  pay	  for	  ﬂight	  development,	  no	  ma\er	  how	  
great	  the	  poten/al	  space	  oﬀers	  and	  no	  ma\er	  how	  
few	  other	  op/ons	  are	  available	  to	  them	  on	  Earth	  to	  
meet	  their	  needs.	  	  	  	  
	  
And	  while	  larger	  companies	  may	  have	  more	  
ﬂexibility	  to	  fund	  research,	  space	  remains	  a	  virtual	  
unknown	  to	  them	  and	  a	  very	  diﬃcult	  place	  to	  
conduct	  work	  compared	  with	  their	  other	  op/ons.	  	  	  
	  
Unless	  they	  have	  no	  choice	  or	  are	  supported	  by	  










“Congress declares that the general welfare of the United States requires that the Administration seek and encourage, to the 
maximum extent possible, the fullest commercial use of space.” 
ESO	  Commercial	  Microgravity	  Case	  Study	  1	  –	  Novice	  Users	  –	  A	  Small	  Business	  Perspective	  
Recommendations	  
	  
Dr.	  Jeanne	  Becker	  fairly	  pointed	  out	  both	  the	  
possibility	  and	  the	  uncertainty	  inherent	  in	  cancer	  
research	  in	  space	  in	  her	  landmark	  review	  ar/cle	  in	  
Nature	  31:	  	  
	  
“Experiments conducted in the microgravity environment 
of space are not typically at the forefront of the mind of a 
cancer biologist.  
 
However, space provides physical conditions that are not 
achievable on Earth, as well as conditions that can be 
exploited to study mechanisms and pathways that control 
cell growth and function.  
 
Over the past four decades, studies have shown how 
exposure to microgravity alters biological processes that 
may be relevant to cancer …  
 
Combination of the resources available in the unique 
environment of microgravity with the tools and advanced 
technologies that exist in the laboratories across Earth may 
inform new research approaches to expand the knowledge 
necessary for improving treatment options, and enhancing 





One	  thing	  is	  clear.	  	  	  
	  
There	  is	  no	  way	  to	  develop,	  or	  even	  
determine,	  the	  value	  of	  removing	  gravity	  for	  
advancing	  this	  type	  of	  potenKally	  life	  saving	  






Therefore,	  it	  is	  strongly	  recommended	  that,	  at	  a	  minimum,	  
NASA	  and/or	  CASIS	  conKnue	  to	  support	  VBI’s	  invesKgaKon	  
through	  ﬂight	  and	  that	  ESO	  monitor	  its	  progress	  because	  
of	  its	  potenKal	  beneﬁt	  to	  public	  health;	  its	  uKlity	  as	  a	  Case	  
Study	  for	  this	  class	  of	  commercial	  biotech	  research	  in	  
space	  for	  a	  terrestrial	  (rather	  than	  space)	  market;	  and	  its	  
value	  in	  understanding	  and	  beher	  developing	  the	  
commercial	  research	  and	  applicaKons	  potenKal	  of	  the	  ISS	  
and	  the	  emerging	  commercial	  space	  transportaKon	  and	  
service	  providers.	  
	  
Further	  it	  is	  strongly	  recommended	  that	  NASA	  establish	  
funded	  solicitaKon	  mechanisms	  to	  encourage	  worthy	  
applicaKons	  R&D	  in	  space,	  at	  least	  through	  the	  iniKal	  ﬂight	  
test,	  when	  such	  studies	  have	  the	  potenKal	  to	  yield	  
important	  public	  beneﬁts,	  even	  if	  they	  don’t	  provide	  a	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Mentors,	  advisors,	  guides	  and	  integrators	  (MAGIs)	  
who	  can	  help	  a	  novice	  craj	  a	  successful	  ﬂight	  
experiment	  -­‐-­‐	  	  like	  those	  at	  Bioserve	  Space	  
Technologies,	  Dr.	  Lawrence	  DeLucas	  at	  University	  of	  
Alabama,	  Nanoracks,	  and	  inves/gator	  ﬂight	  support	  
groups	  at	  NASA	  Centers	  -­‐-­‐	  are	  essen/al	  to	  the	  
development	  of	  the	  ISS	  Na/onal	  Laboratory	  and	  the	  
commercial	  microgravity	  laboratory	  market	  of	  
emerging	  space	  companies.	  	  	  
	  
Because	  they	  play	  such	  essenKal	  roles	  in	  delivering	  
value	  back	  to	  the	  public	  from	  spaceﬂight,	  it	  is	  
recommended	  that	  the	  MAGIs	  be	  supported	  to	  
maintain	  criKcal	  staﬀ	  experKse	  during	  the	  
intervals	  between	  funded	  ﬂight	  developments.	  
	  
Novel	  research	  of	  the	  kind	  that	  can	  lead	  to	  
breakthroughs	  will	  almost	  always	  require	  hardware	  
modiﬁca/on.	  	  
	  
Some	  mods	  will	  be	  rela/vely	  easy	  and	  cheap,	  like	  
those	  required	  by	  Vivo	  Biosciences.	  But	  some	  that	  
are	  important	  for	  opening	  new	  markets	  –	  like	  
onboard	  analyses	  and	  	  the	  ability	  to	  handle	  
sensi/ve	  biological	  samples	  on	  the	  launchpad,	  
through	  the	  launch	  interval,	  	  and	  during	  return	  to	  
Earth	  –	  may	  need	  funding	  in	  the	  $5M-­‐$10M+	  
category.	  
	  
However,	  given	  the	  magnitude	  of	  taxpayer	  invest-­‐
ments	  required	  to	  build	  the	  ISS	  and	  the	  billions	  of	  
dollars	  per	  year	  spent	  in	  operaKng	  it,	  increasing	  
funding	  to	  support	  more	  space	  research	  for	  public	  
beneﬁt	  and	  increasing	  the	  investment	  in	  infra-­‐
structure	  that	  opens	  new	  ﬁelds	  and	  makes	  break-­‐
throughs	  possible	  is	  a	  sound	  and	  worthy	  strategy,	  






Finally,	  it	  is	  strongly	  recommended	  that	  NASA	  and	  CASIS	  
conKnue	  their	  wise	  pracKce	  of	  encouraging	  and	  supporKng	  
excepKons	  to	  standard	  plans	  and	  procurement	  strategies	  
for	  ﬂight	  studies	  when	  “out	  of	  the	  box”	  and	  “out	  of	  the	  
blue”	  proposals	  oﬀer	  the	  potenKal	  for	  excepKonal	  
outcomes	  that	  could	  serve	  the	  public	  in	  important	  ways.	  
	  
Without	  ESO’s	  support	  of	  the	  ﬁrst	  stage	  of	  the	  VBI’s	  ﬂight	  
concept,	  this	  important	  story	  of	  the	  ISS,	  poten/al	  public	  
health	  beneﬁts,	  and	  new	  commercial	  interests	  for	  using	  
space	  would	  not	  have	  been	  told.	  
	  
The	  ﬁndings	  are	  relevant	  and	  /mely,	  not	  only	  to	  NASA	  and	  
CASIS	  who	  are	  working	  to	  amplify	  the	  value	  of	  the	  ISS	  
system	  for	  public	  beneﬁt,	  but	  also	  to	  emerging	  space	  
companies	  seeking	  to	  understand	  the	  needs	  of	  poten/al	  
new	  customers	  for	  the	  economic	  development	  of	  space.	  	  	  
	  
Experiments	  like	  the	  one	  proposed	  by	  Vivo	  Biosciences	  
don’t	  ﬁt	  easily	  within	  tradi/onal	  programma/c	  constraints.	  	  
But	  as	  ojen	  observed,	  new	  discoveries,	  disrup/ve	  
technologies,	  and	  innova/on	  rarely	  do.	  
“Governments	  will	  always	  play	  a	  huge	  part	  in	  solving	  big	  
problems.	  They	  set	  public	  policy	  and	  are	  uniquely	  able	  to	  
provide	  the	  resources	  to	  make	  sure	  solu@ons	  reach	  everyone	  
who	  needs	  them.	  They	  also	  fund	  basic	  research,	  which	  is	  a	  
crucial	  component	  of	  the	  innova@on	  that	  improves	  life	  for	  
everyone.”	  	  Bill	  Gates	  
	  
“Congress declares that the general welfare of the United States requires that the Administration seek and encourage, to the 
maximum extent possible, the fullest commercial use of space.” 
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Image	  1	   Image	  of	  SpaceX	  Dragon	  Capsule	  a\ached	  to	  the	  Interna/onal	  Space	  Sta/on.	  	  Space.Com.	  
h\p://www.space.com/15476-­‐gallery-­‐spacex-­‐capsule-­‐space-­‐sta/on-­‐guide.html	  
	  
Image	  2	   Vivo	  Biosciences	  Clients	  and	  Collaborators.	  New	  High	  Throughput	  Human	  Micro	  Tumor	  Assay	  Playorm	  




Image	  3	   Vivo	  Biosciences	  Hu-­‐Biogel™	  from	  the	  Vivo	  Biosciences	  website.	  h\p://www.vivobiotech.com/	  
Image	  4	   Describes	  how	  Vivo	  Biosciences’	  MicroTumor	  Models	  translate	  into	  clinical	  results	  for	  pa/ent	  drug	  
treatment.	  New	  High	  Throughput	  Human	  Micro	  Tumor	  Assay	  Playorm	  for	  Pre-­‐clinical	  Drug	  




Image	  5	   Describes	  MicroTumor	  Valida/on	  Projects	  with	  Novar/s	  Oncology.	  New	  High	  Throughput	  Human	  Micro	  





Image	  6	   Describes	  Vivo	  Biosciences	  Desired	  Outcomes.	  From	  the	  Vivo	  Biosciences	  website.	  
h\p://www.vivobiotech.com/	  
	  
Image	  7	   Describes	  Vivo	  Biosciences	  Desired	  Outcomes.	  From	  the	  Vivo	  Biosciences	  website.	  
h\p://www.vivobiotech.com/	  
	  
Image	  8	   Image	  of	  VBI	  HuBiogel™	  plus	  human	  tumor	  cells	  in	  BioServe	  Space	  Technologies’	  BioCell	  ini/a/ng	  ﬂight	  




Image	  9	   Image	  showing	  how	  cells	  aggregate	  in	  culture	  and	  diﬀeren/ate	  into	  /ssues.	  Histone	  H1	  Deple/on	  
Impairs	  Embryonic	  Stem	  Cell	  Diﬀeren/a/on.	  Zhang	  Y,	  Cooke	  M,	  Panjwani	  S,	  Cao	  K,	  Krauth	  B,	  et	  al.	  
(2012)	  PLoS	  Genet	  8(5):	  e1002691.	  doi:10.1371/journal.pgen.1002691	  
ESO	  Commercial	  Microgravity	  Case	  Study	  1	  –	  Novice	  Users	  –	  A	  Small	  Business	  Perspective	  









Image	  10	   Early	  design	  of	  NASA’s	  Rota/ng	  Wall	  Vessel.	  NASA	  Educa/onal	  Brief.	  	  NASA’s	  Bioreactor:	  Growing	  
Cells	  in	  a	  Microgravity	  Environment.	  	  EB-­‐2002-­‐12-­‐187-­‐MSFC.	  pdf	  
	  
Image	  11	   Vivo	  Biosciences	  HuBiogel™	  and	  tumor	  beads	  close-­‐up	  in	  BioServe	  BioCell.	  Appendix	  III	  Vivo	  
Biosciences	  Final	  Report.	  
h\ps://dl.dropboxusercontent.com/u/51989053/Vivo%20Biosciences%20Final%20Report/NASA-­‐
Ames%20Vivo%20Report%205-­‐13.pdf	  
Image	  12	   BioServe	  Space	  Technologies	  Logo.	  h\p://www.colorado.edu/engineering/BioServe/	  
Image	  13	   ISS026-­‐E-­‐018760	  (18	  Jan.	  2011)	  -­‐-­‐-­‐	  NASA	  astronaut	  Catherine	  (Cady)	  Coleman,	  Expedi/on	  26	  ﬂight	  
engineer,	  performs	  a	  Capillary	  Flow	  Experiment	  (CFE)	  Interior	  Corner	  Flow	  2	  (ICF-­‐2)	  test.	  The	  CFE	  is	  
posi/oned	  on	  a	  Maintenance	  Work	  Area	  in	  the	  Des/ny	  laboratory	  of	  the	  Interna/onal	  Space	  
Sta/on.	  CFE	  observes	  the	  ﬂow	  of	  ﬂuid,	  in	  par/cular	  capillary	  phenomena,	  in	  microgravity.	  	  	  
	  
Image	  14	   Ar/st	  Compsite	  drawing	  showing	  possible	  future	  synergies	  for	  space	  biotech	  work.	  	  L.	  Harper.	  	  NASA	  
ARC.	  
Image	  15	   Photograph	  of	  BioServe’s	  CGBA	  during	  Increment	  33	  showing	  open	  containment	  volume	  and	  sample	  
canisters.	  Image	  courtesy	  of	  NASA.	  
h\p://www.nasa.gov/mission_pages/sta/on/research/experiments/CGBA.html	  
Image	  16	   NASA	  Image:	  ISS004E11048	  -­‐	  Commercial	  Generic	  Bioprocessing	  Apparatus	  (CGBA)	  Isothermal	  
Containment	  Module	  (ICM)	  v.3,	  installed	  in	  EXpedite	  the	  PRocessing	  of	  Experiments	  to	  Space	  Sta/on	  
(EXPRESS)	  rack	  4	  just	  above	  Expedi/on	  4	  ﬂight	  engineer	  Dan	  Bursch's	  extended	  lej	  arm.	  
	  
Image	  17	   Expedi/on	  8	  Commander	  and	  Science	  Oﬃcer	  Michael	  Foale	  conducts	  an	  inspec/on	  of	  the	  
Microgravity	  Science	  Glovebox.	  
h\p://spaceﬂight.nasa.gov/gallery/images/sta/on/crew-­‐8/hires/iss008e20622.jpg	  
	  

































Appendix	  IV:	  	  Vivo	  Biosciences	  Presenta/on	  to	  
Tricon	  on	  results	  of	  blind	  studies	  for	  cancer	  
research	  with	  Champion	  Oncology	  and	  Novar/s	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